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Abstract 
Anesthetized, recumbent horses commonly develop hypoxemia secondary to 
ventilation/perfusion (VA/Q) mismatch and shunting of pulmonary blood (Qs/Qt) 
through atelectatic lung regions. Hypoxemia in the anesthetized horse is difficult to 
treat and ventilatory therapy is often ineffective. Nitric oxide (NO) can be inhaled 
(iNO) to provide selective dilatation of pulmonary blood vessels with no systemic 
effects. However, conventional continuously delivered iNO is ineffective in the 
anesthetized horse. Conversely, pulse-delivered iNO (PiNO) may be effective and the 
lower PiNO dose could reduce the risk of NO accumulation in the anesthetic circuit, 
alleviating adverse effects from NO accumulation. However, a rapid and profound 
decrease in oxygen (‘rebound effect’), potentially mediated by endothelin-1 (ET-1), can 
occur with abrupt cessation of iNO at the end of anesthesia and this would limit the 
usefulness of PiNO in the horse since recovery is a critical period. PiNO decreases 
VA/Q mismatch but the mechanism is unknown. The aims were to determine the 1) 
pulse dose, efficacy and safety of PiNO during prolonged inhalation anesthesia and 
during recovery from anesthesia, and 2) mechanism of improved pulmonary function. 
PiNO increased oxygen and decreased Qs/Qt in both dorsally (Paper I) and laterally 
(Paper II) recumbent horses for an approximate surgical duration (2.5 hours) when 
PiNO was delivered at the most effective pulse duration (first 30-45% of the first part 
of inspiration; Paper I). The efficacy continued into recovery following PiNO cessation 
and PaO2 was higher and Qs/Qt lower in PiNO horses than in control horses for the 
entire recovery period. No rebound effect occurred in horses still anesthetized or those 
recovering from anesthesia. ET-1 concentrations were not increased by PiNO. No 
residual NO was present in the breathing circuit. The mechanism of PiNO as 
determined by multiple inert gas elimination technique (MIGET) was improved 
matching of VA and Q. With scintigraphy, the improvement was determined to be due 
to a movement of blood against gravity from the dependent, atelectatic regions of the 
lung to the non-dependent aerated portions of the lung. 
In conclusion, we have shown that PiNO is effective and safe in anesthetized horses 
and recovering horses. PiNO redistributes blood flow from dependent to non-dependent 
regions of the lung, thereby decreasing Qs/Qt and improving VA/Q matching. We are 
confident that PiNO is ready for clinical use in anesthetized horses. 
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1 Introduction 
1.1   Hypoxemia in the anesthetized horse 
For a myriad of reasons, horses, like other animals, often require surgery under 
general anesthesia with positioning in either dorsal or lateral recumbency. 
Unfortunately, general anesthesia and recumbent positioning can create 
physiologic changes that have a much greater adverse impact in the equine 
patient than in smaller mammalian patients. General anaesthesia in the horse 
routinely impairs pulmonary gas exchange with a significant decrease in the 
partial pressure of arterial oxygen (PaO2), with values commonly below 10 kPa 
(75 mm Hg) and even below 8 kPa (60 mmHg), in spite of the fact that most 
patients are breathing  >0.95 fraction of inspired oxygen (FiO2)  (Hall, 
Gillespie and Tyler 1968, Gillespie, Tyler and Hall 1969, Mitchell and 
Littlejohn 1974, Nyman and Hedenstierna 1989, Nyman et al. 1990, Keegan et 
al. 1991, Day et al. 1995). In these patients, oxygen-hemoglobin saturation 
(SaO2) also decreases and the pulmonary shunt (Qs/Qt) and partial pressure of 
alveolar-arterial oxygen difference P(A-a)O2 increase, indicating significant 
pulmonary dysfunction. Positioning in dorsal (or supine) recumbency, which is 
a common position for horses under anesthesia, can profoundly exacerbate the 
hypoxemia when compared to hypoxemia occurring in lateral recumbency 
(Swanson and Muir 1986, Stegmann and Littlejohn 1987, Nyman, Funkquist 
and Kvart 1988, Nyman and Hedenstierna 1989, Steffey et al. 1990, Gasthuys, 
de Moor and Parmentier 1991, Day et al. 1995, Whitehair and Willits 1999). 
Because oxygen is a vital substrate for normal tissue function, low PaO2, or 
hypoxemia, can cause numerous problems depending on which cells, tissue or 
organs are affected by the decrease in oxygen delivery. In horses, hypoxemia 
associated with anesthesia has been directly implicated in postanesthetic 
cerebral necrosis (McKay et al. 2002), sudden cardiac arrest (McGoldrick, 
Bowen and Clarke 1998), hepatic insult (Whitehair et al. 1996), decreased 
skeletal muscle oxygenation (Steffey, Willits and Woliner 1992, Whitehair et 14 
 
al. 1996, Portier et al. 2009), increased serum lactate (Portier et al. 2009) and 
lactic acidemia (Taylor 1999).  
Horses have a fairly high rate of anesthesia-related morbidity and mortality 
(Young and Taylor 1993, Mee, Cripps and Jones 1998, Johnston et al. 2002, 
Proudman et al. 2006, Bidwell, Bramlage and Rood 2007, Senior et al. 2007, 
Wagner 2008a) especially when compared to anesthesia-related morbidity and 
mortality reported in other species. Recently reported rates of anesthesia-
related mortality are 1.9% in the horse (with an increase in mortality in 
unhealthy horses) (Johnston et al. 2002), 0.17% in dogs (Brodbelt et al. 2008), 
0.24% in cats (Brodbelt et al. 2008) and 0.001% in humans (Bainbridge et al. 
2012). Hypoxemia could potentially contribute to morbidity and mortality, 
especially in unhealthy horses, which often have a greater oxygen deficit than 
healthy horses (Edner, Nyman and Essen-Gustavsson 2007, McCoy et al. 
2011).   
Of the four phases of anesthesia (premedication, induction, maintenance 
and recovery), the anesthetic recovery period is generally the most dangerous 
phase of anesthesia for the horse (Richey et al. 1990, Young and Taylor 1993, 
Johnston et al. 2002, Franci, Leece and Brearley 2006, Senior et al. 2007, 
Bidwell et al. 2007, Wagner 2008a) and Day et al. (Day et al. 1995) stated that 
the presence of hypoxemia, as defined as PaO2 <60 mmHg, ‘indicates higher 
morbidity and higher incidence of postanesthetic complications, including 
arrhythmias, pulmonary insufficiency, pneumonia, and postanesthetic 
myositis’.  Poor muscle perfusion caused by hypotension is directly implicated 
in anesthesia-related myopathies and neuropathies (Grandy et al. 1987, Richey 
et al. 1990, Young and Taylor 1993, Duke et al. 2006), however, the damage is 
probably due to decreased oxygen delivery and ischemia rather than to the 
mere presence of hypotension. Finally, horses with high PaO2 at the end of 
anesthesia had recoveries that were faster and of equal quality compared to 
horses with low PaO2 (Hopster et al. 2011). Faster recoveries that are still good 
quality, could be beneficial since time in recumbency can increase the 
likelihood of some post-anesthetic complications (eg, myopathy, neuropathy).  
 
1.2  Causes of hypoxemia 
To correct the problem we must first understand the cause of the problem. 
Hypoxemia has five causes: 1) decreased FiO2, 2) impaired oxygen diffusion 
across the alveolar-arterial membrane, 3) hypoventilation, 4) alveolar 
ventilation/perfusion (VA/Q) mismatch, and 5) shunting of deoxygenated blood 
directly from the venous to the arterial circulation (Qs/Qt).  Decreased FiO2 15 
 
could be a concern in anesthetized patients if the inspired oxygen was mixed 
with air, nitrous oxide, or some other gas that dilutes the concentration of 
inspired oxygen. However, nitrous oxide is rarely, if ever, used in horses and, 
although air mixtures are used, hypoxemia commonly occurs in horses 
breathing a wide range of FiO2, with FiO2 of 0.95-1 the most commonly 
administered. However, high FiO2 can contribute to hypoxemia by causing 
absorption atelectasis but, in the horse, this is a slow developing source of 
hypoxemia (Nyman et al. 1988) which can generally be alleviated with 
initiation of positive pressure ventilation early in the anesthetic period (Day et 
al. 1995). Thus, decreased or increased FiO2 can be ruled out as the major 
cause of hypoxemia in the anesthetized horse. Diffusion impairment can also 
be ruled out as a common cause of hypoxemia in healthy, anesthetized horses.  
Hemoglobin is completely saturated with oxygen in the first 1/3 of the red 
blood cell transit time through the pulmonary capillary. Thus, saturation in 
patients without pulmonary disease is limited by perfusion rather than by 
diffusion. There is ample time for oxygenation, even if mild diffusion 
impairment exists. Moderate to severe interstitial lung disease, such as 
profound pulmonary edema, would be required to impair diffusion to the extent 
that oxygenation would be impaired. Horses with that degree of respiratory 
disease are unlikely to undergo anesthesia for clinical procedures and horses in 
anesthesia research studies reporting hypoxemia were healthy and free from 
pulmonary disease or dysfunction. Thus, diffusion impairment is unlikely to be 
a routine cause of hypoxemia in the anesthetized horse.  
The three remaining causes of hypoxemia (hypoventilation, VA/Q mismatch 
and Qs/Qt) all contribute to hypoxemia in anesthetized horses. 
Hypoventilation, which is common in anesthetized horses, will cause an 
increase in the partial pressure of alveolar carbon dioxide (PACO2) and this 
contribution to hypoxemia is evidenced by the alveolar gas equation:  
  
 PAO2 = PIO2(PB-47) - (PACO2)/0.8  
  
  In this equation, PAO2 is the partial pressure of alveolar oxygen, PiO2 is 
the partial pressure of inspired oxygen, PACO2 is the partial pressure of 
alveolar carbon dioxide (which is generally approximated by the partial 
pressure of arterial carbon dioxide [PaCO2]), and 0.8 is the respiratory 
exchange ratio that relates CO2 production to oxygen consumption (ie, 
normally 0.8 mole of CO2 is produced for every 1 mole of O2 consumed). 
Because arterial oxygen depends on a pressure gradient from alveolar oxygen, 
decreased PAO2 directly leads to decreased PaO2. Fortunately, hypoventilation 
is easily diagnosed using arterial blood gas analysis and easily remedied using 16 
 
mechanical ventilation (most commonly intermittent positive pressure 
ventilation; IPPV) to improve alveolar ventilation and eliminate excess 
PACO2. Furthermore, PaO2 in anesthetized horses can be as low as 8 kPa (60 
mmHg), which, according to the alveolar gas equation, would require an 
extremely high PACO2 if hypoventilation were the sole cause of hypoxemia in 
a horse. Thus, hypoventilation can be eliminated as the primary cause of 
hypoxemia in patients that are adequately ventilated. In addition, hypoxemia 
often persists even after hypercarbia has been remedied, emphasizing that other 
factors are causing the hypoxemia.  
The other two conditions, VA/Q mismatch and Qs/Qt, represent a bigger 
problem for the horse as they are neither easily diagnosed nor easily treated. 
VA/Q mismatch occurs in lung areas that are well-ventilated but poorly 
perfused or well-perfused but poorly ventilated, with a continuous spectrum of 
VA/Q matching from low VA/Q (minimal ventilation) to high VA/Q (minimal 
perfusion) (Figure 1). Blood perfusing poorly ventilated alveoli (on left in 
Figure 1) is returned to the systemic circulation without having been fully 
oxygenated, thus contributing to hypoxemia. Blood perfusing high VA/Q 
alveoli (on right in Figure 1) is well-oxygenated but is a small portion of total 
blood flow and thus does not balance the impact of hypoxemic blood returning 
from the low VA/Q regions.  
 
 
 
Figure 1.  Diagram of ventilation (VA) and perfusion matching. The alveolus on the left is poorly 
ventilated but adequately perfused (low VA/Q), the alveolus in the middle has appropriate 
matching of VA/Q and the alveolus on the left is adequately ventilated but poorly perfused (high 
VA/Q). Note the PaO2 impact of blood perfusing the alveolus on the left  (large decrease in PaO2) 
versus the PaO2 impact of blood perfusing the alveolus on the right (no impact)(West 2011) 
 
 
 
VA/Q mismatch was long thought to be the primary cause of hypoxemia in 
the anesthetized horse because anesthesia reduces functional residual capacity 17 
 
(FRC) to volumes at which airway closure could occur more easily (McDonell 
1974, Sorenson and Robinson 1980) and reduces both ventilation (McDonell 
1974) and blood flow (Stolk 1980) to the dependent lung regions. Thus, 
perfusion and ventilation are not always in the same place at the same time and 
it was theorized that anesthesia creates a low VA/Q state leading to hypoxemia.  
However, it is actually shunt of blood through unventilated alveoli (designated 
Qs/Qt for ratio of shunted blood flow [Qs] to total blood flow [Qt]) that is the 
major cause of hypoxemia in the anesthetized horse.  The deoxygenated blood 
from the shunt, termed ‘venous admixture’, is delivered directly into systemic 
circulation without being oxygenated and causes a decrease in PaO2. In the 
standing conscious horse, Qs/Qt is approximately 1% as determined by the 
multiple inert gas elimination technique (MIGET)(Hedenstierna et al. 1987, 
Nyman, Bjork and Funkquist 1999), which is the gold standard for 
determination of the degree of shunt. This normal, low-level shunt is present in 
most (or perhaps all) mammalian species and is caused by deoxygenated blood 
from the bronchial veins (which transport blood from the pulmonary veins) and 
the Thebesian (or coronary) veins (which transport blood from the 
myocardium). Unlike other modalities used to determine venous admixture, 
MIGET can be used to differentiate Qs/Qt from areas of low VA/Q and in the 
Nyman and Hedenstierna MIGET study (Nyman and Hedenstierna 1989) areas 
of low VA/Q were minimal to absent in spontaneously breathing anesthetized 
horses in either dorsal or lateral recumbency, while Qs/Qt was increased to 
approximately 34% in dorsally recumbent and 20% in laterally recumbent 
horses. Thus, it would appear that Qs/Qt is the predominant problem.   
This was further demonstrated when, using computed tomography (CT) and 
histologic analysis of lung tissue (Figure 2), large areas of complete atelectasis 
were identified in the dependent lung regions of ponies and horses anesthetized 
with halothane in oxygen and placed in dorsal recumbency (Nyman et al. 
1990). In this study, the size of the atelectatic regions correlated to the degree 
of hypoxemia, emphasizing that the atelectatic regions were the direct cause of 
the hypoxemia. Clearly, areas that are completely atelectatic would be perfused 
but not ventilated and would cause Qs/Qt rather than low VA/Q.   
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Figure 2. On the left is a CT scan from a pony showing the large area of consolidation in the 
dependent lung fields (indicated by arrows). On the right are the lungs from a horse euthanized 
during anesthesia. Note the large consolidated area (indicated by a circle) in the dependent lung 
fields (Nyman et al. 1990).  Both images courtesy of Dr. Nyman.  
 
Although both compression and absorption atelectasis can contribute to 
hypoxemia, the fact that these densities developed within 20 minutes of placing 
the horses in dorsal recumbency (Nyman et al. 1990) indicates that they were 
due to compression atelectasis. The rapid development of atelectasis was 
previously demonstrated by radiography in anesthetized horses in lateral 
recumbency (McDonell, Hall and Jeffcott 1979). The shape of the equine 
diaphragm and the large size of the equine gastrointestinal tract are responsible 
for this compression (Sorenson and Robinson 1980). The diaphragm slopes 
dramatically under the caudal lung fields in the standing horse, allowing the 
liver and a large portion of the lung field to rest above the intestines, but also 
allowing the intestines to compress the caudal lung fields in a recumbent horse 
since recumbency places the intestines above the lung fields. (Figure 3) 
Absorption atelectasis can exacerbate the compression-induced hypoxemia but 
the effect is usually is a slow decline in PaO2 over time rather than an almost 
immediate decline in PaO2 following recumbency (Nyman et al. 1988).  
 
 19 
 
 
Figure 3. Schematic of a horse in dorsal recumbency. The arrow indicates the viscera resting on 
the caudal lung lobes causing atelectasis. Figure courtesy of Dr. Nyman. 
 
Interestingly, collapsed lung regions identified by computed tomography 
(CT) scan are generally larger in proportion to body size and the impairment of 
oxygenation and percent of venous admixture are greater in anesthetized 
ponies (Nyman et al. 1990) than respective indices in anesthetized humans or 
sheep (Brismar et al. 1985, Strandberg et al. 1986, Hedenstierna et al. 1989). 
These differences emphasize the fact that anesthesia causes greater pulmonary 
compromise in the horse than in other species and the greater degree of 
compromise is most likely ‘related to different vertical lung heights and the 
effect of hydrostatic forces’ (Nyman et al. 1990) and to the visceral 
compression of the caudal lung fields as described above. 
 
1.3  Treating hypoxemia in anesthetized horses: Changing 
ventilation 
 
Standard changes in ventilation (including common techniques like IPPV 
and/or positive end-expiratory pressure [PEEP]), and more advanced 
ventilatory techniques (including ventilation of selective lung fields or alveolar 
recruitment manuevers) have been utilized in an attempt to improve 
oxygenation in anesthetized horses.  Alterations in the composition of inspired 
gas, such as decreased FiO2 or the addition of helium, have also been tried. 
IPPV does cause a decrease in PACO2 and can also improve oxygenation 
(Steffey et al. 1977, Gasthuys et al. 1991, Edner, Nyman and Essen-
Gustavsson 2005). However, PaO2 is not always improved (Shawley and 
Mandsager 1990, Nyman et al. 1990, Day et al. 1995) and IPPV may impair 
cardiovascular function, as evidence by decreased Q and ABP secondary to 
IPPV-mediated positive intra-thoracic pressure (Hodgson et al. 1986, Shawley 20 
 
and Mandsager 1990, Nyman et al. 1990, Gasthuys et al. 1991, Edner et al. 
2005, Steffey et al. 2005a, Steffey et al. 2005b). In addition to the causes of 
hypoxemia that have been listed, hypoxemia can also occur secondary to 
decreased cardiac output (Qt) since inadequate pulmonary perfusion will 
decrease the amount of blood that reaches ventilated alveoli to be oxygenated. 
Thus, IPPV can make oxygenation worse rather than better (Day et al. 1995). 
Positive end expiratory pressure (PEEP) is often utilized to recruit low VA/Q 
alveoli with the hopes of improving gas exchange. Although PEEP is more 
likely than IPPV alone to improve oxygenation, this technique does not always 
increase PaO2 and has an even greater negative effect on the cardiovascular 
system than IPPV used alone (Beadle, Robinson and Sorenson 1975, Swanson 
and Muir 1988, Wilson and Soma 1990, Nyman et al. 1990). PEEP may also 
have an adverse effect on the Qs/Qt as increased intrathoracic pressure, while 
expanding alveoli, may also redistribute blood into the atelectatic area (Nyman 
et al. 1990) 
Because standard IPPV and PEEP do not always improve oxygenation in 
anesthetized horses, specialized ventilatory techniques have been investigated. 
In dorsally recumbent horses, the dependent lung regions have been selectively 
intubated and inflated using PEEP while the non-dependent lung regions have 
been intubated and ventilated by spontaneous breathing (Nyman et al. 1987, 
Nyman and Hedenstierna 1989). In laterally recumbent horses, each lung field 
(dependent and non-dependent) has been intubated and ventilated separately 
(Moens et al. 1994, Moens et al. 1998). With both of these techniques, PaO2 
was improved and Qs/Qt was decreased. However, the techniques required 
specialized endotracheal tubes, intubation through a tracheotomy site and two 
anesthesia machines to ventilate each portion of the lung, thus these techniques 
are not practical for routine use.  Also, recruitment maneuvers of 60-80 cmH20 
peak inspiratory pressure (held for 10-12 seconds) have been used in an 
attempt to improve oxygenation in anesthetized horses (Hopster et al. 2011).  
PaO2 in horses receiving the recruitment maneuver was significantly higher 
than PaO2 in control horses at all times, but repeated recruitment was necessary 
to sustain the improvement. Furthermore, the recruitment maneuver did cause a 
cardiovascular impact and horses in the recruitment group required more 
dobutamine than control horses to maintain the same mean arterial blood 
pressure (MAP).  Finally, the increased pressure techniques may not be benign 
for the aerated areas of the lung. Even in horses breathing spontaneously with 
no increase in inspiratory pressure, histologic exam of the aerated lung 
revealed evidence of hyperinflation and alveolar wall fragmentation (Nyman et 
al. 1990). 21 
 
In addition to changing ventilatory techniques, improving oxygenation by 
changing the ventilatory gas has been attempted in anesthetized horses. Most 
horses under general anesthesia receive >0.95 FiO2 but decreasing the FiO2 to 
0.21 in horses maintained on total intravenous anesthesia (TIVA) caused a 
decrease in Qs/Qt when compared to horses maintained on the traditional 0.95 
FiO2 (Marntell, Nyman and Hedenstierna 2005b). Horses maintained with 
inhalation anesthesia had a lower P(A-a)O2 when FiO2 was 0.3 than when it 
was 0.85 (Cuvelliez et al. 1990). However, decreasing the FiO2 to 0.5 in horses 
anesthetized with inhalant anesthesia did not change Qs/Qt (Hubbell et al. 
2011), thus, merely decreasing the FiO2 may not eliminate the problem in all 
horses. Adding helium to the inspiratory mixture (added as a carrier gas in 
place of nitrogen) did decrease the P(A-a)O2 (Staffieri et al. 2009) but most 
anesthetic machines are not equipped to deliver helium. Moreover, in all of the 
studies listed here, PaO2 was lower in horses receiving FiO2 of anything <0.95. 
Decreased PaO2 is not likely to be concerning as long as arterial oxygenation 
stays in the normal range. However, low FiO2 may result in a PaO2 in the 
hypoxemic range, necessitating a therapeutic increase in FiO2 (Nyman et al. 
1990). In some patients, low PaO2 can be predicted by low pulse pressure, 
emergency procedure, and dorsal positioning (Whitehair and Willits 1999) and 
this set of criteria describes a major portion of the equine anesthesia caseload, 
the horse with abdominal compromise or ‘colic’. Colic patients are highly 
likely to be hypoxemic and may not tolerate lower FiO2.  Thus decreasing the 
FiO2 may not always be the answer for improving oxygenation in the 
anesthetized horse.   
 
1.4  Treating hypoxemia in anesthetized horses: Changing 
perfusion 
 
With changes in ventilation often ineffective at improving oxygenation and 
often deleterious for the cardiovascular system, the question arises: can we 
alter perfusion instead of ventilation to achieve improvement in oxygenation in 
anesthetized horses?   
1.4.1  Systemically administered drugs  
Administration of the positive inotrope dobutamine improved cardiac output 
and, thus, likely improved pulmonary perfusion but did not improve PaO2. 
(Swanson and Muir 1986).  Although disappointing, this outcome is not wholly 
surprising since improving blood flow to the entire lung would increase flow 22 
 
not only to the ventilated lung regions, but to the non-ventilated lung regions as 
well, thereby maintaining, or perhaps even exacerbating, the degree of Qs/Qt. 
Clenbuterol administered intravenously (Gleed and Dobson 1990, Keegan et al. 
1991) and albuterol administered as an inhalant (Robertson and Bailey 2002) 
have been used with some success to increase PaO2 in anesthetized horses. 
Although inhaled albuterol may relieve bronchoconstriction and improve 
ventilation, the most likely mechanism of action of both drugs is increased 
pulmonary blood flow as both heart rate and cardiac index are increased during 
administration of the drugs. As with dopamine, this can also worsen 
hypoxemia secondary to a more profound VA/Q mismatch (Dodam et al. 1993), 
which would explain why this treatment commonly fails. Furthermore, both 
compounds can cause tachycardia and/or profound sweating in the horse. 
Systemically administered vasodilating drugs, which are used some in 
human medicine to relieve pulmonary arterial hypertension (PAH) and 
improve oxygenation, may also cause hypotension and, as previously 
mentioned, hypotension is as deleterious as hypoxemia to the anesthetized 
horse (Grandy et al., 1987, Richey et al., 1990, Young and Taylor, 1993, Duke 
et al., 2006). Furthermore, systemic vasodilating drugs can worsen Qs/Qt as 
described above for dobutamine and the buterols. In human medicine, a 
selective pulmonary vasodilator, nitric oxide (NO) is often delivered as an 
inhaled gas (iNO) to selectively dilate the pulmonary vessels and improve 
oxygenation without affecting the systemic vasculature (Ichinose, Roberts and 
Zapol 2004).  
1.4.2 Nitric  oxide  (NO) 
Nitric oxide (NO) is a small molecule of soluble gas that was identified in 1987 
as the elusive ‘endothelium-derived relaxing factor’ (EDRF) (Palmer 1987).  
Intriguingly, before this discovery, NO was not viewed as a useful molecule 
but instead was known primarily as a toxic air pollutant. However, after 1987, 
the importance of NO as a biological molecule quickly became apparent and 
NO was named ‘Molecule of the Year’ by Science magazine in 1992 and in 
1998, Robert F. Furchgott, Louis J. Ignarro and Ferid Murad were jointly 
awarded the Nobel Prize in Physiology or Medicine for their discovery of 
‘nitric oxide as a signaling molecule in the cardiovascular system’(Zetterstrom 
2009).  
1.4.3  NO production, mechanism of action and termination 
NO and the amino acid citrulline are formed from L-arginine and oxygen by 
one of the nitric oxide synthase (NOS) enzymes (Figure 4). There are 3 major 
forms of NOS: 1) endothelial NOS (eNOS), which is a calcium-dependent 23 
 
NOS that is constitutively produced in the endothelium; 2) neural NOS 
(nNOS), another calcium-dependent NOS that is constitutively produced in the 
brain and in a variety of peripheral nerves; and 3) inducible NOS (iNOS), a 
calcium-independent NOS that is not constitutive but that is induced by 
inflammatory and immunological processes (Ray, Chakraborti and Gulati 
2007).   
 
 
 
Figure 4. Formation of NO and citrulline from L-arginine. NOS can be eNOS, iNOS or nNOS. 
 
Because NO is uncharged, the molecule is readily diffusible and, once 
formed, diffuses out of the cell where it was generated and into the target cell. 
The role of NO as EDRF is the best described, and perhaps the most important, 
function of the molecule. As EDRF, NO is continuously released into the 
vascular by the endothelium in response to various stimuli. NO causes an 
increase in cyclic guanosine monophosphate (cGMP) in the target cell and this 
leads to a relaxation of vascular smooth muscle and subsequent vasodilation 
(Stamler et al. 1994, Ichinose et al. 2004). Through these mechanisms, 
endogenous NO regulates both systemic and pulmonary vascular tone (Stamler 
et al. 1994, Blitzer et al. 1996). After inducing smooth muscle relaxation, NO 
rapidly diffuses into the bloodstream and immediately reacts with oxygenated 
hemoglobin to form methemoglobin and nitrate. The majority of the NO is 
excrete as nitrate in the urine (Ichinose et al. 2004).  
1.4.4  Endogenous NO in the equine pulmonary system 
Endogenous NO is present in fairly high amounts in the upper airways of 
mammals and has been measured in the exhalate of humans (Hedenstierna and 
Hogman 1998, Cikach and Dweik 2012), primates (Schedin et al. 1997) and 
elephants (Schedin et al. 1997). Inhalation of endogenous NO from the 
nasopharyngeal region may play a role in homeostatic VA/Q matching in 
humans (Sanchez Crespo et al. 2010).  Although NO was  not measured in 
equine exhalate in one study (Schedin et al. 1997), results show that exhaled 
NO is released from the airways of the horse and may contribute to the 
regulation of pulmonary vascular tone during exercise (Mills et al. 1996). NO 
was also measured in the exhalate of anesthetized horses and the 
concentrations were different depending on whether the horse was 24 
 
anaesthetized with halothane or a combination of ketamine, guaiphenesin and   
romifidine (Marlin et al. 2001). Tissue studies have also been used to identify 
endogenous NO in the equine pulmonary vasculature. Using isolated equine 
pulmonary arteries MacEachern et al. (MacEachern, Smith and Nolan 2004), 
determined that NO is involved in the hypoxic pulmonary vasoconstriction 
(HPV response) and Pelletier et al (Pelletier et al. 1998) determined that 
regional differences in endothelium-mediated relaxation are caused by regional 
differences in the magnitude of the endothelial release of nitric oxide. In the 
intact horse, administration of the NOS inhibitor N(omega)-nitro-L-arginine 
methyl ester (L-NAME) in standing horses caused a significant rise in 
pulmonary arterial pressures, indicating that endogenous NO plays a primary 
role in control of pulmonary vascular tone (Manohar and Goetz 1998). 
Although manipulation of endogenous pulmonary NO may be 
therapeutically effective in some species (Brown et al. 1992, Rafiei, 
Aghadavoudi and Hojjat 2012), the ability to therapeutically manipulate 
endogenous NO in the pulmonary system of the horse is unclear. Decreased 
production of endogenous NO using the NOS inhibitor L-NAME had no effect 
on oxygenation in strenuously exercising horses (Manohar and Goetz 1998). 
Also, increased production of endogenous NO through administration of the 
NO precursor L-arginine failed to improve PaO2 in anesthetized horses (Lerche 
2006). If neither decreased or increased endogenous NO production had any 
effect on oxygenation, perhaps exogenously administered NO may be a better 
therapeutic choice in hypoxemic horses.  
1.4.5  Inhaled exogenous NO  
As an exogenously administered inhaled gas, NO causes selective dilation of 
pulmonary blood vessels in ventilated areas, which causes reduction of 
pulmonary vascular resistance and improved blood flow to the lung regions 
exposed to the inhaled NO (Frostell et al. 1991, Frostell et al. 1993). This 
allows a redistribution of pulmonary blood flow to the better ventilated alveoli, 
thus decreasing venous admixture and improving PaO2.  NO absorbed into the 
pulmonary capillaries is rapidly scavenged by hemoglobin and inactivated 
(Bloch et al. 2007), thus limiting the systemic impact.  The first reports of the 
use of iNO in humans and research animals occured in the late 1980’s and 
early 1990’s (Frostell et al., 1991, Frostell et al., 1993). Although primarily 
licensed for treating PAH in neonates, iNO is now widely used to treat a wide 
variety of pulmonary diseases that cause pulmonary hypertension and 
hypoxemia (Ichinose et al., 2004, Griffiths and Evans, 2005, Bloch et al., 2007, 
Creagh-Brown et al., 2009).  25 
 
As with many exogenously administered compounds, iNO also has the 
potential to cause adverse effects.  High concentrations of NO can react with 
oxygen to form the toxic gas NO2.  This gas acts mainly as a respiratory 
mucosal irritant but high dosages may induce more toxic effects (Weinberger 
et al. 2001). In some species, abrupt cessation of inhaled NO (iNO), such as 
might occur at the end of an anesthetic period, can cause a ‘rebound effect’, 
which is a rapid and potentially drastic decrease of PaO2 and increase of 
pulmonary arterial pressure (PAP) to values that are significantly worse than 
pre-iNO levels and the rebound effect may be related to a compensatory 
increase in the circulating concentration of the potent endogenous 
vasoconstrictor endothelin-1 (ET-1) (Chen et al. 2001, McMullan et al. 2001, 
Wedgwood et al. 2001, Pearl et al. 2002).  
 
1.4.6  Inhaled nitric oxide in horses  
In spite of the fairly wide-spread use of iNO in humans and the potential utility 
of iNO in horses, very little of the gas has been used in equine research and 
none has been used in clinical patients. In fact, prior to the work presented 
here, a total of 6 papers regarding the use of iNO in horses had been published.  
In the first report of iNO in the horse, the gas caused bronchodilation in horses 
with experimentally-induced bronchoconstriction, but no markers of 
oxygenation were measured (Sweeney, Tomasic and Russell 1999).  Inhaled 
NO was also used to reduce pulmonary hypertension in maximally exercising 
horses, but again no indices of oxygenation were measured (Kindig et al. 
2001).   In the first report of iNO used to improve oxygenation in horses, PaO2 
was not increased in horses maintained with inhalant anesthesia and continuous 
delivery of iNO (CiNO) (Young et al. 1999). However, CiNO did improve 
PaO2 and SaO2 in foals with experimentally-induced pulmonary hypertension 
(Lester, DeMarco and Norman 1999).  
Then, in 2001 and 2002 Heinonen et al. (Heinonen et al. 2001, Heinonen et 
al. 2002), demonstrated that iNO delivered as a pulse (PiNO) to anesthetized 
horses significantly increased PaO2 and decreased Qs/Qt without causing 
adverse effects. Timing of the pulse was critical for these changes and PaO2 
was increased and Qs/Qt decreased if the pulse was delivered during the early 
portion of the inspiration but was less effective, or not effective, if delivered 
throughout a greater percentage of inspiration or during the mid to latter part of 
the breath rather than at the beginning.  The advantage of PiNO is that a lower 
dose of iNO is utilized, making the accumulation of exhaled NO and the 
production of NO2 less likely. PiNO is easy to utilize since a tank of medical 
grade NO can be connected directly to the breathing system without the need 26 
 
for adapting the anesthesia machine. Also, the amount of PiNO mixed with 
oxygen is very small and does not impact the FiO2.  Because of its efficacy, 
safety and ease of use, PiNO has the potential to revolutionize equine 
anesthesia. However, PiNO use must be moved from the anesthesia research 
laboratory to anesthesia in a clinical setting prior to its use in equine patients.   
1.5  Preparing PiNO for clinical use in anesthetized horses  
In the efficacy and safety studies by Heinonen et al. (Heinonen et al. 2001, 
Heinonen et al. 2002), PiNO was delivered to anesthetized horses for intervals 
of 5 minutes.  Unfortunately, the duration of equine surgery is rarely less than 
one hour and more likely to be 2-3 hours. Although iNO is used for long 
duration therapy in humans (Bloch et al. 2007, Ichinose et al. 2004, Barst et al. 
2012), there is some evidence that prolonged duration therapy does not always 
provide a sustained improvement in oxygenation (Day, Allen and Witte 1997). 
The sustainability of the response to long-term delivery of PiNO, the minimum 
effective pulse length for long-duration delivery,  and the potential 
accumulation of excess NO and production of NO2 in the anesthesia circuit 
with prolonged administration all need to be determined. Also, surgery in the 
horse is done in both lateral and dorsal recumbency and the effects of PiNO in 
different recumbencies delivered for surgical durations are unknown. As stated 
in the introduction, horses positioned in lateral recumbency are less likely to 
experience hypoxemia than those positioned in dorsal recumbency (Nyman et 
al. 1988, Day et al. 1995) and it is possible that the degree of VA/Q mismatch 
and, thus, the magnitude of the response to PiNO could be insignificant in 
lateral recumbency. Conversely, horses in lateral recumbency develop high 
P(A-a)DO2 (Nyman et al. 1988, Day et al. 1995) and  Qs/Qt (Nyman and 
Hedenstierna 1989) and PiNO delivery may improve pulmonary function even 
in the presence of adequate PaO2. Furthermore, in the previous studies utilizing 
PiNO in anaesthetized horses (Heinonen et al. 2001, Heinonen et al. 2002)  
there were no control groups and it is possible, albeit unlikely, that 
oxygenation improved with time rather than with treatment.  
The effects of discontinuing PiNO in anesthetized horses has been briefly 
examined following the 5 minute delivery times but has not been examined 
following long-term delivery and has not been evaluated following 
discontinuation of PiNO, isoflurane and 100% oxygen.  As stated, the 
anesthetic recovery period is the most dangerous phase of anesthesia for the 
horse (Johnston et al. 2002, Wagner 2008a) and any factors that further 
jeopardizes the recovery period would be unacceptable. If the previously 
described rebound effect occurs following PiNO use in horses, it could limit 27 
 
the usefulness of this technique during anesthesia. Because the recovery phase 
is so important in the horse, assessment of the impact of PiNO on recovery is 
critical. 
Finally, the mechanism of action of PiNO is generally, but not precisely, 
known and understanding the mechanism is an important aspect of safe and 
effective use of the therapy. The matching of the distribution of pulmonary 
blood flow and ventilation can be determined by the multiple inert gas 
elimination technique (MIGET) but MIGET does not provide regional 
anatomical data (Wagner 2008b). The actual spatial distribution (or 
redistribution) of blood flow in the lungs can be visualized in two dimensions 
by perfusion scintigraphy, which could be used to determine the spatial 
redistribution of blood flow in anesthetized horses. 
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2  Aims of the thesis 
The hypothesis was that PiNO would improve oxygenation in anesthetized 
horses through spatial redistribution of pulmonary blood flow resulting in 
decreased shunt and better matching of perfusion to the ventilated regions of 
the lung without causing adverse effects either during anesthesia or in 
recovery. 
 
With the goal of introducing PiNO for clinical use in isoflurane-anesthetized 
horses, the aims of our study were to determine the:  
1.  range of PiNO pulse durations that provide the maximal effect at 
lowest dose, 
2.  efficacy and safety of uninterrupted long-term administration of PiNO 
in horses positioned in dorsal and lateral recumbency,  
3.  safety and physiologic effects of PiNO discontinuation in anesthetized 
horses,  
4.  safety and physiologic effects of PiNO discontinuation on the 
anesthetic recovery period, and  
5.  ventilation/perfusion matching and spatial distribution of perfusion 
during PiNO.  
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3  Materials and Methods 
3.1 Horses 
 Six healthy Standardbred horses (2 mares and 4 geldings) with a mean weight 
of 488 kg (range 450-510 kg) and a mean age of 5 years (range 4-6 years) were 
used in studies I and III. Ten healthy Standardbred horses (8 mares and 2 
geldings) with mean weight of 513 kg (range 476-550 kg) and a mean age 9 
years (range 5-13 years) were used for studies II and IV. Three additional 
healthy Standardbred horses (2 mares and 1 gelding) with a mean weight of 
504 kg (range 458-581 kg) and a mean age of 6 years (range 3-8 years) were 
used in the MIGET portion of study 2. Three healthy Standardbred horses (1 
mare and 2 geldings) with a mean weight of 513 kg (range 459-562 kg) and the 
mean age of 9 years (range 8-9 years) were used for Study V.  
3.2 Treatment  Groups   
In studies I, III and V, all horses received PiNO and all of the horses were in 
one group. In Study II there were two groups and the horses were divided so 
that 6 horses were in the control group (C group) that received inhalant 
anesthesia but no PiNO and 6 received inhalant anesthesia plus PiNO (PiNO 
group). Two horses were anesthetized in both groups and they were 
randomized in a cross-over design and anesthetized at intervals of no less than 
four weeks between studies. In study IV all horses were recovering from 
anesthesia (isoflurane, 100% oxygen discontinued) and were divided into two 
groups: 6 horses recovering from anesthesia + PiNO delivery and 6 horses 
recovering from anesthesia that did not include PiNO delivery. As with study 
II, 2 horses were used in both groups and they were randomized in a cross-over 
design and anesthetized at intervals of no less than four weeks between studies. 32 
 
3.3 Anesthesia 
A standard anesthetic protocol was used for Studies I, II, III and V; horses in 
study IV were anesthetized with same technique but data were not collected 
during anesthesia. Food but not water was withheld for 12 hours prior to 
anesthesia. On the day of the procedure, a complete physical exam was done to 
insure that all horses were healthy. After the exam, 0.03 mg/kg
-1 acepromazine 
(Plegicil; Pharmacia & Upjohn Animal Health, Sweden) was administered 
intramuscularly to each horse. Approximately 30 minutes after the injection of 
acepromazine 7.5% guaifenesin (Myolaxin; Chassot & Cie AG; Switzerland) 
was infused IV until the horse developed ataxia (approximately 100 mg/kg
-1). 
Anesthesia was then induced with the intravenous (IV) administration of a 
bolus of thiopental sodium (4 to 5 mg/kg
-1, Pentothal Natrium; Abbott, 
Sweden). The horse was intubated with a 24-mm cuffed endotracheal tube and 
placed in left lateral recumbency on a padded table. The endotracheal tube was 
connected to a semiclosed circle rebreathing system that was attached to a 
large-animal anesthesia machine. Anesthesia was maintained with spontaneous 
breathing of oxygen (FiO2 > 0.95) and isoflurane (Forene; Abbott, Sweden) 
delivered through an out-of-circle, agent-specific, precision vaporizer. 
Throughout the study, end-tidal isoflurane concentrations of 1.5% to 1.7% 
(approximately 1.2-1.25 times the minimum alveolar concentration of 
isoflurane in horses) were maintained.  The gas monitor was calibrated before 
each research period by use of a commercially prepared calibration gas.  All 
horses were allowed to equilibrate under anesthesia for 45 minutes (Studies I, 
II and III) or 60 minutes (Study V), during which time they were instrumented 
for data collection.  
3.4  Instrumentation (Studies I, II, III, V) 
All horses were instrumented with ECG electrodes placed for lead II analysis 
and measurement of heart rate. The skin over the facial artery was clipped free 
of hair and aseptically prepared and a 20-gauge, 5-cm catheter was introduced 
percutaneously for measurement of arterial blood pressure and for collection of 
arterial blood samples for blood gas analysis. An area over the right jugular 
vein was clipped free of hair and aseptically prepared; an introducer kit was 
used to place a 7-F thermodilution catheter through the jugular vein and into 
the pulmonary artery for measurement of pulmonary arterial blood pressure 
and for collection of mixed venous blood samples for blood gas analysis. A 
pig-tail, multiport catheter was introduced by the same technique into the same 
jugular vein, advanced to the right ventricle, and retracted into the right atrium 
for injection of saline (0.9% NaCl) solution for cardiac output (Qt) 33 
 
determination. Catheters were positioned by use of pressure-tracing guidance 
and simultaneous ECG monitoring and were locked in position via a Luer-lock 
adapter. Systolic, diastolic, and mean arterial blood pressure (ABP) values 
(SAP, DAP, MAP, respectively) and systolic, diastolic and mean arterial 
pulmonary pressure (SPAP, DPAP, MPAP, respectively) were measured by 
use of pressure transducers positioned at the level of the sternal manubrium, 
which (Qt) was considered to correspond to the level of the right atrium. 
Cardiac output was determined by use of a thermodilution technique in which a 
bolus of 20 mL of cold (0
oC) saline solution was injected rapidly by hand 
through the pig-tailed catheter. A minimum of 3 injections was performed, and 
the data were averaged at each time period. Cardiac output, systemic arterial 
blood pressures, heart rate (HR), FiO2, respiratory rate (RR), tidal volume 
(TV), partial pressure of end-tidal carbon dioxide (PETCO2), and end-tidal 
isoflurane concentration were recorded from a standard anesthesia monitor 
(AS/3- AM™ anesthesia monitor; Datex-Ohmeda, Finland). 
3.5  Instrumentation (Study IV)  
The area over the artery was clipped free of hair and aseptically prepared and a 
20-gauge, 5-cm catheter was introduced percutaneously into the facial artery 
for collection of arterial blood samples for blood gas analysis. An area over the 
right jugular vein was clipped free of hair and aseptically prepared and an 
introducer kit was used to place a 7-F thermodilution catheter through the 
jugular vein and into the pulmonary artery for collection of mixed venous 
blood samples for blood gas analysis. Heart rate was counted by manual 
palpation of the facial artery and respiratory rate was counted by watching 
thoracic excursions. Other commonly used anesthetic monitors (eg, ECG, pulse 
oximeter, cardiac output computer) were not utilized in the recovery portion of 
the study as the presence of an abundance of monitoring equipment in the 
recovery stall was deemed dangerous.  
3.6 PiNO  Delivery   
A standard delivery technique, described below, was used for studies I, II and 
V. In Studies III and IV PiNO was delivered in the method described but data 
were collected following PiNO cessation. Once completely instrumented, the 
horses were allowed to equilibrate under anesthesia for 45 minutes (Studies I 
and II) or 60 minutes (Study V), data were then collected and used as 
anesthesia baseline data (T45). After baseline data collection, PiNO delivery 
commenced. The PiNO was delivered during the initial portion of inhalation 34 
 
during each breath by use of a proprietary device that was designed at the 
Datex-Ohmeda Research Unit, Helsinki, Finland specifically for pulsed 
delivery of iNO during spontaneous breathing. The device was activated by 
negative pressure and delivered a volumetric dose into the endotracheal tube at 
the onset of inspiration in the same manner as previously described (Heinonen 
et al. 2001, Heinonen et al. 2002). The delivery device was connected to a port 
located at the proximal end of the endotracheal tube. The NO was supplied in a 
cylinder of 2,000 ppm medical grade NO in N2 (AGA AB, Sweden). In Study I 
and the MIGET portion of Study II, the dose of PiNO was measured using an 
AD-lite (Datex-Ohmeda, Finland) and expired NO was monitored with a 
chemiluminescent analyser prototype (Datex-Ohmeda, Finland) connected 
between the Y-piece and the point of NO administration.  The analyzer was 
calibrated with the mixture 100 L/L NO in N2 (Aga AB, Lidingö, Sweden) 
and with room air depleted of NO with a charcoal absorber.  The monitor was 
used to determine the end-tidal and peak expired NO fractions. 
3.7  Methods for MIGET (Studies II (MIGET) and V (MIGET)) 
The distribution of ventilation and perfusion was estimated by a multiple inert 
gas elimination technique (MIGET; Wagner et al. 1974; Hedenstierna et al. 
1987) in Study II (this portion of the study designated Study II (MIGET)) and 
Study V (designated Study V (MIGET)). After anesthesia as described above, 
an infusion of six inert gases (sulphur hexafluoride, ethane, cyclopropane, 
enflurane, ether and acetone; combined and dissolved in isotonic sodium 
chloride solution) was begun into the jugular vein at 30 ml*min
-1, during which 
time the horses were instrumented as described above. After 60 minutes of 
infusion and instrumentation, arterial and mixed venous blood samples were 
drawn, and mixed expired gas was collected from a heated mixing box 
connected to the expiratory limb of the large animal circle (Figure 5 a & b). 
Gas concentrations in the blood samples and exhalate were measured by a gas 
chromatograph (Hewlett Packard 5890 series II, GA, USA). From the blood- 
and mixed expired gas the VA/Q was calculated according to the original 
technique (Hedenstierna et al. 1974).  Blood flow (Qt) and standard deviation 
of its logarithmic distribution (log SDQ), tidal volume (VT) and standard 
deviation of its logarithmic distribution (log SDV), right to left vascular shunt 
% of the Qt (QS; perfusion of lung regions with VA/Q<0.005), and dead space 
% of the VT (VD; ventilation of lung regions including apparatus dead space 
with VA/Q>100) were measured.  
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Figure 5. a (on left) view of heated mixing box (at left of photo); b (on right) view of anesthesia 
machine modifications to an open breathing system for MIGET exhalant gas collection. Note that 
the exhalation limb of the breathing circuit is not connected to the anesthesia machine. It connects 
to the heated mixing box. 
 
 
3.8  Methods for scintigraphy (Study V) 
Perfusion scintigrams of the caudal lung fields were made using a large field of 
view gamma camera fitted with a general purpose low energy collimator 
(Picker SX 300, Picker International Inc., Cleveland. OH, USA) at the same 
times that the MIGET was determined. An aliquot of 500 Mbq of 
99mTc-
macroaggregated human serum albumin (MAA: Macroaggregated albumin, 
TechneScan LyoMAA, Mallinckrodt AB, Sweden) was prepared using 
standard methods (Votion and LeKeux 2003) and injected slowly over a period 
of 1 minute, which included 3 breaths in Horses 1 and 2 and 8-10 breaths in 
horse 3, to ensure even distribution throughout the lung (Votion and LeKeux 
2003). Images were acquired and processed using a nuclear medicine program 
controlling the gamma camera (Hermes Medical Systems
®, Hägersten, 
Sweden).  Each study was made as a dynamic acquisition at a rate of 2 seconds 
per frame (picture) for one minute, with a resolution of 256x256 pixels. 
Pulmonary perfusion was studied in each horse at prePiNO, PiNO and 
postPiNO. Neither the camera head nor the horses were moved between 
studies. 
As each 2-second frame had a poor signal-noise ratio due to relatively few 
scintillation points, the edges of the lungs were poorly defined. All frames 
were filtered with a medium resolution Metz (fast fourier transform) filter to 
remove the high frequency components (noise) and produce definite margins 
of the lungs. In order to eliminate motion unsharpness due to breathing, frames 
acquired during the expiratory pause were identified as the smallest-sized lung 
field and frames larger than these (caused by breathing) were removed from 36 
 
the data set.  Twenty of the expiratory images from each study were randomly 
chosen so that each study then contained 20 frames, which were summed as a 
single static 10 second image. This process was repeated for each horse at 
PrePiNO, PiNO and PostPiNO.  
To compensate for the decay of the tracer 
99mTc, the static expiratory 
images collected at pre-PiNO were corrected for the loss of radioactivity 
during the time from their acquisition to the time of the acquisition of images 
collected at PiNO. Also, the images acquired at PostPiNO included 
background radioactivity from the injections at PrePiNO and PiNO. This 
background activity was subtracted from the images acquired at PiNO and 
PostPiNO.
  
To produce images that showed the redistribution of blood flow, the activity 
in each pixel in the PiNO image was subtracted from the pixel activity in the 
pre-PiNO image (Figure 6). The resulting functional image identified the areas 
that increased and decreased in activity due to NO inhalation. The border 
between the areas of increase and decrease was a well-defined narrow zone 
where the perfusion did not change. Regions of interest (ROIs) were drawn by 
hand around the two areas of change. The ROIs were copied and pasted onto 
the images just described and the total activity in each ROI for the 9 images 
was recorded. All ROIs were drawn and measured 4 times. Averaged counts 
for each ROI in the images of the PiNO and PostPiNO studies were plotted as 
percentage change from the baseline study. 
 
 
 
Figure 6. Functional images of the caudal lung of the three horses. The left border is defined by 
the diaphragm, the lower border by the spine, and the right border by the edge of the field of view 
of the gamma camera. The yellow line defines the ventral region of interest (ROI), in which 
counts increased after inhalation of nitric oxide (NO), indicating increased blood flow. The white 
line defines the dorsal ROI, in which counts, and flow decreased. The images were made by 
subtracting the NO treatment image from the baseline image.  This created pixels with negative 
numbers (black) where flow increased, and colored pixels where flow decreased, scaled according 
to the relative color scale for each image. To facilitate drawing the ROIs, especially at the 
isocount line between them, the color scales were adjusted to enhance the contrast between the 
two ROIs. 
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Each filtered study for each horse was again examined frame-by-frame and 
the frames at maximal inspiration were extracted and saved as a summed static 
image. This data group was not limited to 20 frames because the data was used 
only to calculate the area of a ROI, not radioactivity within a ROI. ROIs 
around the entire lung field of each of these static images were drawn 
automatically as an isocount line at a threshold of 15% of the maximum 
counts/pixel. The areas as a number of pixels were recorded for peak 
inspiration and expiration and the difference between them was averaged for 
each horse. This number gave an indication of the relative tidal volumes. 
 
3.9  Blood gas analysis (Studies I-V) 
Arterial and mixed venous blood samples were obtained for assessment of 
arterial pH (pHa), mixed venous pH (pHv ̄ ), partial pressure of oxygen in 
arterial blood (PaO2), saturation of hemoglobin with oxygen in arterial blood 
(SaO2), partial pressure of oxygen in mixed venous blood (Pv ̄ O2), saturation of 
hemoglobin with oxygen in mixed-venous blood (Sv ̄ O2), partial pressure of 
carbon dioxide in arterial blood (PaCO2), and partial pressure of carbon 
dioxide in mixed venous blood (Pv ̄ CO2). Arterial and mixed venous oxygen 
saturation were measured with a standard electrode technique (ABL 500; 
Radiometer, Denmark) and blood haemoglobin (Hb) concentrations were 
measured spectrophotometrically (OSM 3; Radiometer, Denmark). Samples for 
blood gases were stored on ice until analysis. Blood gas values were corrected 
for atmospheric pressure but not body temperature and P50 in the horse. 
3.10 Endothelin-1 analysis (Studies II-IV) 
Mixed venous blood was collected in chilled tubes containing EDTA (final 
concentration, 10mM) and centrifuged at 4
oC for 10 minutes to separate the 
plasma which was subsequently analyzed for ET-1 concentration. Acid ethanol 
was added to precipitate the protein. The precipitate was analyzed for ET-1–
like immune reactivity by use of a radioimmunoassay involving antiserum 
raised against ET-1 in rabbits, which are immunized for antibody production at 
the laboratory performing the assays. The detection limit of the assay was 1.91 
picomol, the intraassay variation was 6% and the inter-assay variation was 
14%. The cross-reactivity of the E1 antiserum was as follows: ET-1, 100%; 
ET-2, 27%; ET-3, 8%; and big ET-1, 0.14%. The plasma concentration of ET-
1 was expressed as picomol per mL of plasma.  38 
 
3.11 Calculated data (Various studies)   
Shunt fraction (Qs/Qt) was calculated using the following formula: 
Qs/Qt = (Cc’O2 – CaO2)/(Cc’O2 – C v ̄ O2) 
where Cc’O2, CaO2, and Cv ̄ O2 are oxygen content of capillary, arterial, and 
mixed venous blood, respectively. These values were calculated as: CxO2= 
(1.36 x haemoglobin  concentration x SxO2) + (0.003 x PxO2) 
 
Alveolar-arterial oxygen difference P(A–a)O2 as calculated using:  
PAO2 - PaO2 
where PAO2 is the partial pressure of oxygen in the alveoli.  
 
Partial pressure of alveolar oxygen (PAO2) was calculated using:  
FiO2 – (PACO2/R) 
where PaCO2 was used as PACO2 (the partial pressure of carbon dioxide in the 
alveoli) and R is the respiratory quotient (0.8). FiO2 is the fraction of oxygen in 
the inspired air. 
3.12 Determination of the PiNO Pulse Length 
In order to determine the most effective duration of pulse delivery for each 
horse (Studies I and II), a flow sensor detecting gas flow was fitted onto the 
endotracheal tube to trigger the delivery of iNO during the first portion of 
inspiration in three separate predetermined steps of increased pulse duration. 
The durations were designed to correspond to approximately 20%, 30%, 45% 
and 60% of the total inspiratory time in Study I. Because the 20% inspiratory 
time was fairly ineffective, it was not used in Study II so only 30%, 45% and 
60% were used in Study II. The horses were allowed to equilibrate at each 
pulse length for 15 minutes and then data were collected before the subsequent 
pulse length was initiated.  Pulse duration was not randomized. The pulse 
length that corresponded to the highest (peak) PaO2 in the individual horses 
was delivered for the remainder of each study. In Study II (MIGET), PiNO was 
pulsed at 30% and 60% of the inspiratory time for 15 minutes each. Based on 
the data collected in Studies I and II PiNO45% was chosen for Study V. 
3.13 Data Collection (see time lines at the bottom of this section) 
3.13.1   Studies I and II  
All data including HR; SAP, MAP and DAP; SPAP, MPAP and DPAP; FiO2; 
RR; TV; Hb; ETiso; pHa and pHv ̄ ; PaO2; Pv ̄ O2; SaO2; Sv ̄ O2; P(A-a)DO2;  and 39 
 
Qs/Qt were measured or calculated following 45 minutes of equilibration after 
commencement of isoflurane anesthesia prior to NO administration (T45) and 
after each 15 minute increase in PiNO (T60, T75, T90 and T105 for Study I; 
T60, T75 and T90 for Study II ) and then every 15 minutes for the duration of 
the study (T105, T120, T135 and T150). Cardiac output was determined at 
T45, T105 and T135. Mixed venous blood samples were collected for ET-1 
analysis at T45 and T150. 
3.13.2   Study II (MIGET)  
Data were collected after 60 minutes of anesthesia equilibration without PiNO 
(baseline). Following baseline data collection, NO delivery commenced as 
described above. NO was pulsed during the first 30% and 60% of inspiration, 
respectively and data were collected 15 minutes after equilibration at each 
percentage of PiNO (PiNO30% and PiNO60%). The order of delivery was not 
randomized.  
3.13.3   Study III  
Data including HR; SAP, MAP and DAP; SPAP, MPAP and DPAP; FiO2; RR; 
TV; Hb; ETiso; pHa and pHv ̄ ; PaO2; Pv ̄ O2; SaO2; Sv ̄ O2;[A-a]DO2; and Qs/Qt 
were measured or calculated at the time that the PiNO was discontinued (T0) 
and every minute for 10 minutes (T1 through T10), followed by every 5 
minutes for 20 minutes (T15 through T30) for a total of 30 minutes of data 
collection. All data were collected or calculated at PT0, PT1, PT5, PT10, 
PT25, and PT30 minutes. At all other times, all data were measured or 
calculated except for pHv, Pv ̄ O2, Sv ̄ O2, Qt, P(A–a)O2, and Qs/Qt. Venous 
blood samples for ET-1 analysis were collected at PT0, PT10 and PT15 
minutes. 
3.13.4   Study IV  
All data including HR; RR; pHa and pHv ̄ ; PaO2; Pv ̄ O2; SaO2; Sv ̄ O2; P(A-a)O2; 
and Qs/Qt were measured or calculated at the time that the isoflurane, oxygen 
and PiNO were discontinued (T0) and every two minutes for 10 minutes (T2-
T10), followed by every 5 minutes for 20 minutes (T15-T30) for a total of 30 
minutes of data collection. 
3.13.5   Study V  
All data including HR; SAP, MAP and DAP; SPAP, MPAP and DPAP; RR; 
TV; pHa, pHv; PaO2; Pv ̄ O2; SaO2; Sv ̄ O2; Qt; and ET-1 concentration were 
measured or calculated following 60 minutes of anesthesia equilibration 
(PrePiNO), following 30 minutes of PiNO delivery (PiNO) and 30 minutes 40 
 
after PiNO cessation (PostPiNO). At the same times, MIGET and scintigraphy 
examinations were performed.  
 
3.14 Time lines for data collection 
 
3.14.1   Study 1: Long term delivery of PiNO in dorsally recumbent horses 
 
0 mins             45 mins (T45)            105 mins (T105)              150 mins (T150) 
|-------------------------|----------------------------|----------------------------------------| 
Instrumentation &  Determination of  PiNO delivery & data 
Equilibration   PiNO  pulse  length  collection 
   (4  PiNO  increments) 
 
Data collected at times (T):  T45 (anesthesia baseline), T60, T75, T90, T105, 
T120, T135, T150 
 
3.14.2   Study II: Long term delivery of PiNO to laterally recumbent horses  
 
0 mins             45 mins (T45)      90 mins (T90)                   150 mins (T150) 
|-------------------------|-------------------------|-------------------------------------------| 
Instrumentation &      Determination of    PiNO delivery & data 
Equilibration          PiNO pulse length    collection 
            (3 PiNO increments) 
 
Data collected at times (T): T45 (anesthesia baseline), T60, T75, T90, T105, 
T120, T135, T150 
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3.14.3   Study III: Following cessation of PiNO during isoflurane anesthesia & 
FiO2 >0.95  
 
0 mins (T0)    10 mins (T10)          30 mins (T30)             
|----------------------|-------------------------------------------| 
Discontinue PiNO     Data collection every  Discontinue anesthesia 
but not anesthesia;     5 mins under anesthesia  & move horse to recovery 
Data collection  
every minute. 
 
Data collected at PostPiNO times (T): T0, T1, T2, T3, T4, T5, T6, T7, T8, T9, 
T10, T15, T20, T25, T30 
 
3.14.4   Study IV: Recovery following cessation of PiNO, isoflurane & FiO2>0.95  
 
0 mins (T0)    10 mins (T10)          30 mins (T30)   
|----------------------|-------------------------------------------| 
Discontinue       Data collection every 5 mins  Horse standing 
PiNO, 100% O2  
& isoflurane 
simultaneously. 
Data collection  
every 2 minutes.  
 
Data collected at recovery times (T): T0, T2, T4, T6, T8, T10, T15, T20, T25, 
T30 
 
3.14.5   Study V: MIGET and Scintigraphy before, during and after PiNO delivery  
 
0 mins        60 mins               90 mins                       120 mins  
    (PrePiNO)                  (PiNO)              (PostPiNO) 
|-----------------------------|---------30 min-----------|---------30 min-------------| 
Instrumentation &      PiNO delivery           No PiNO delivery 
inert gas  
administration  
 
Data collected at PrePiNO, PiNO and PostPiNO 
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3.15 Data Analysis 
Studies I-IV: Data were assessed for normal distribution using the Shapiro-
Wilk test. Repeated measures ANOVA was used to compare data within and 
between groups.  The Bonferroni significant difference test was used for post 
hoc comparisons. 
 
Study V: Data were assessed for normal distribution using the Shapiro-Wilk 
test. Repeated measures ANOVA was used to compare physiologic data within 
and between groups. For each horse, measurement and event (PrePiNO 
[baseline], PiNO [treatment] and PostPiNO [recovery]), the ratio 
Dorsal/(Dorsal+Ventral) was calculated for the counts in each ROI. This ratio 
was compared between time points using a mixed-effects ANOVA with horse 
as a random factor and event as a fixed factor. The Bonferroni significant 
difference test was used for post hoc comparisons.. 
 
Data from II (MIGET) and V (MIGET) were presented as descriptive data 
only. 
 
For all statistical calculations, a software package (GraphPad Prism, GraphPad 
Software, CA, USA) was used and a value of p < 0.05 was considered 
significant. 
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4  Results and Discussion  
 
4.1  Preparing for Clinical Use: Efficacy of PiNO 
 
 PiNO pulsed in the first 30-45% of the inhalation phase of the breath caused 
an increase in arterial (PaO2 and SaO2) and mixed venous (Pv ̄ O2 and Sv ̄ O2) 
oxygenation and a decrease in Qs/Qt in horses anesthetized long term in dorsal 
(Study I) or lateral (Study II) recumbency, anesthetized following 
discontinuation of PiNO (Study III), recovering from anesthesia following the 
discontinuation of isoflurane, 100% oxygen and PiNO (Study IV) and during 
short-term delivery in dorsal recumbency for the scintigraphy study (Study V). 
PiNO also improved VA/Q matching as determined by MIGET (Studies II and 
V) and caused a redistribution of blood from dependent to non-dependent lung 
regions as determined by scintigraphy (Study V). Thus, PiNO is efficacious 
and provides beneficial changes in gas exchange and pulmonary function 
during and after isoflurane anesthesia in healthy horses.  
 
4.1.1  Determination of effective pulse duration 
In humans, iNO has traditionally been delivered continuously so that it is 
inhaled throughout the entire inspiratory period (Barst et al. 2012).  However, 
more recently, PiNO has been utilized as pulse of iNO delivered at the 
beginning of inspiration (Channick et al. 1996, Ivy et al. 1998, Kitamukai et al. 
2002, Ivy et al. 2003, Pepke-Zaba and Morrell 2003, Vonbank et al. 2003, 
Barst et al. 2012) and this technique was used in our Studies I, II and V and 
prior to data collection in Studies III and IV. To determine the shortest duration 
of PiNO delivery that would effectively increase PaO2 and decrease Qs/Qt, the 
pulses were delivered at different percentages of the inspiratory time in Studies 44 
 
I and II (Table 1).  Based on the efficacy of pulses in these studies, PiNO45% 
was chosen for Study V. 
 
 
 
 
 
 
 
 
Table 1. Studies in which iNO was delivered beginning with the onset of inhalation. Pulse length 
is described as percentage of the duration of the inhalation phase of the breath. 
 
 
Administration of PiNO at all pulse lengths improved PaO2 and Qs/Qt 
compared to baseline (Table 2; Figure 7) in all horses but one (Study II 
(MIGET) Horse 3).  
 
 
 
Study 
Number 
 PaO2 in kPa and 
[mmHg] 
Qs/Qt 
(%) 
# of horses 
with maximum 
 Improvement 
(total # of 
horses in the 
study) 
I  Baseline   12.6±4.1 [95±31]  32 ± 2   
I  20%  20.8±6.2 [156±47]  29 ± 3  0 (6) 
I  30%  24.2±6.6 [182±59]  23 ± 4  4 (6) 
I  43%  24.3±6.7 [182±50]  22 ± 4  2 (6) 
I  73%  23.9±6.6 [179±50]  24 ± 2  0 (6) 
II  Baseline  26.9±10.8 [202±81]  28 ± 7   
II  30%  38.5±7.3 [289±55]  22 ± 2  4 (6)  
II  45%  37.2±8.1 [279±61]  22 ± 3  2 (6) 
II  60%  36.9±8.8 [277±66]  23 ± 7  0 (6) 
II 
(MIGET) 
Baseline  18.7±5.2 [140±39]  39 ± 5   
II 
(MIGET) 
30%  30.4±4.6 [228±35]  30 ± 3  3 (3) 
II 
(MIGET) 
60%  27.7±0.2 [194±2]  33 ± 3  0 (3) 
 
Table 2. Effects of differing pulse lengths on PaO2 and Qs/Qt. Baseline = no PiNO 
Study Number  Pulse length as a percentage of the 
duration of inhalation  
I  20%, 30%, 43% and 73% 
II  30%, 45% and 60% 
II (MIGET)  30% and 60% 
V 45% 45 
 
However, the pulse length producing the peak effect varied among the 
individual horses (Figure 7). In Study I, the delivery of PiNO20% improved 
PaO2 but the improvement was not significant in all horses.  The maximum 
increase in PaO2 and decrease in Qs/Qt occurred at PiNO30% in 4 horses and 
at PiNO45% in 2 horses. In Study II, the maximum increase of PaO2 occurred 
at PiNO30% in 4 horses and PiNO45% in 2 horses. Qs/Qt was not significantly 
different among those pulse lengths. Both PiNO73% (Study I) and PiNO 60% 
(Studies II and II (MIGET)) not only failed to provide a further increase in 
PaO2 in most horses but actually caused a slight decrease in PaO2 and increase 
in Qs/Qt in 2 horses in Study I (Figure 7) when compared to the PiNO45%. In 
Horse 3 Study II (MIGET), PiNO60% caused a deterioration in PaO2, Qs/Qt 
and log SDQ to values below (PaO2) or above (Qs/Qt, log SDQ) baseline 
(prePiNO) values. However, that horse had a fairly high PaO2 at baseline and 
the PaO2 values were never in the hypoxemic range nor were the changes 
significant.  
 
 
 
 
Figure 7. Individual horse (n=6) response to PiNO administered in four different pulse lengths 
(average 20%, 30%, 43% and >65% of the inspiratory time; Study I) on arterial oxygen tension 
(PaO2).  
 
In addition to the pulse lengths listed in the table, data that was not 
published in Study II (MIGET) was collected when PiNO was delivered during 
the middle 50-85% of the breath. With this delivery, there was a decrease in 
PaO2 and an increase in Qs/Qt compared to PiNO30% and PiNO60% in two 
horses and no change in the third horse. Thus, we have shown that a short pulse 
of PiNO is optimal for improved pulmonary function and that the short pulse 
needs to be synchronized with the beginning of inhalation. These results are 
similar to those from previous studies in which iNO pulsed into the first phase 46 
 
of inhalation was more effective than iNO pulsed during the late phase of 
inhalation (Heinonen et al. 2001, Heinonen et al. 2002). Based on this body of 
work, we believe that it is the pulsed-delivery – and the duration and timing of 
that pulse – that is crucial for maximum effects from PiNO.  
CiNO does improve PaO2 in some human patients but fails to provide 
improvement in others (Ichinose et al. 2004, Griffiths and Evans 2005, Bloch 
et al. 2007, Creagh-Brown, Griffiths and Evans 2009). Just as CiNO did 
increase PaO2 in conscious foals with experimentally induced pulmonary 
hypertension (Lester et al. 1999) but failed to increase PaO2 in adult halothane-
anesthetized horses (Young et al. 1999). Based on the success of the pulse 
delivery technique in our studies, we propose that PiNO might provide a more 
consistent response than CiNO. PiNO has recently been introduced in human 
medicine and appears to be as equally efficacious and safe as CiNO in a review 
of initial trials (Barst et al. 2012). The rationale for the success of PiNO is 
based on the probable distribution of iNO within the lungs and the fact that 
both timing and duration of the pulse should result in iNO distribution to 
aerated lung regions (Heinonen, Hogman and Merilainen 2000, Heinonen, 
Merilainen and Hogman 2003).   
PiNO delivered in the early phase of inhalation will selectively reach the 
lung regions that are ventilated but poorly perfused. Because alveoli that are 
distended are easier than collapsed alveoli to fill with air, gases entering the 
airways during the initial phase of inhalation move easily into the well-
ventilated alveoli. Once these alveoli are filled, inhaled gases begin to move 
into alveoli that are in the so-called transitional or border zone (the zone 
between ventilated and atelectatic alveoli; Figure 8).  
 
 
Figure 8.  From a sketch on the left and a histological slice of tissue on the right we see alveoli 
that are A=inflated; B=border zone; C=atelectatic (Lapinsky and Mehta 2005).   
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Transitional or border zone alveoli are not fully distended and have a fairly 
high closing volume, which means that they do not open with every breath 
(low VA/Q). Thereby, these alveoli do not consistently participate in gas 
exchange. CiNO allows distribution to all alveoli that can be opened, including 
those that are intermittently open and poorly ventilated, whereas delivery of 
PiNO during the early phase of inhalation allows selective NO distribution 
only to the consistently open, well-ventilated alveoli. The iNO-mediated 
vasodilation and increased blood flow to well-ventilated alveoli improves PaO2 
because blood flowing to these alveoli becomes fully saturated with oxygen 
with every breath. Conversely, the iNO-mediated vasodilation and increased 
blood flow to intermittently ventilated alveoli could fail to increase, and could 
even decrease, the systemic PaO2 since blood perfusing those alveoli could 
return to circulation without becoming fully saturated with oxygen. 
Furthermore, these areas of poor ventilation would normally not receive a high 
percentage of blood flow because of hypoxic pulmonary vasoconstriction 
(HPV). Even a small uptake of NO with subsequent vasodilation could 
potentially counteract the local HPV, thereby increasing perfusion in the low 
VA/Q and shunt regions of the lung with a subsequent decrease in PaO2.  These 
effects could potentially contribute to the failure of NO to improve 
oxygenation during CiNO. The PaO2 impact of perfusion of low VA/Q regions 
of the lung is demonstrated by the alveoli on the left in Figure 1  in the 
introduction. 
However, the shortest pulse of 20% of the inhalation time used in Study I 
was only moderately effective and this could be due to the fact that the pulse is 
actually too short. The earliest percentage of delivered PiNO fills the 
deadspace (ventilated portions of the airway that do not participate in gas 
exchange) and reaches only a small number of ventilated alveoli, thus making a 
minimal impact on PaO2. Conversely, with the longest pulse lengths, (73% in 
Study I and 65% in Study II), the iNO, in addition to being distributed to 
ventilated lung regions, could reach into the boundary zone between ventilated 
and atelectatic lung regions and this could explain why these longer pulse 
lengths failed to further improve pulmonary function when compared to the 
intermediate duration iNO pulses. In Studies I and II the initial improvement of 
PaO2 and Qs/Qt with pulse lengths of 30%-45% followed by the deterioration 
in the same parameters with the longer pulse lengths supports the theory that 
iNO delivered as a pulse in the first part of inhalation reaches the alveoli that 
are actively participating in gas exchange, while continuing the delivery 
reaches transitional or border zone alveoli.  48 
 
4.1.2  Indices of efficacy and physiologic data  
PiNO administered to hypoxemic horses improved arterial (PaO2 and SaO2) 
and venous (Pv ̄ O2 and Sv ̄ O2) oxygenation and decreased Qs/Qt. Since inhaled 
NO is rapidly inactivated by hemoglobin in the pulmonary circulation, 
systemic effects of the gas should be minimal to absent and this is evidenced 
by our data in which no changes in Qt or ABP occurred. Minor respiratory 
depression (as evidenced by increased PaCO2 and decreased pHa) did occur in 
all horses and was exacerbated in the PiNO horses. All other physiologic 
variables had minor or insignificant changes. 
 
PaO2 and SaO2  
Partial pressure O2 (PaO2) dissolved in blood and the percentage of 
hemoglobin saturated with O2 (SaO2) are commonly used to evaluate 
pulmonary function since the primary role of the lung is to bring O2 into the 
body while eliminating CO2 from the body.  
 
Effects during anesthesia 
PiNO increased both PaO2 and SaO2 in anesthetized horses in Studies I, II and 
V. The results of Study II are particularly interesting because the inclusion of 
the control group allowed an assessment of the magnitude of the improvement 
in oxygenation with PiNO. In this study, both the PaO2 and the SaO2 were 
significantly higher in the PiNO horses than in the C horses throughout the 
entire anesthetic period (Figure 9).  In these laterally-recumbent horses, both 
PaO2 and SaO2 were fairly high at baseline so the values for these parameters 
were not significantly greater than baseline at any point in the PiNO horses. 
However, both PaO2 and SaO2 were significantly lower than baseline in the C 
horses at the last 3 data collection times.  Our horses were fairly deeply 
anesthetized and anesthetic depth affects ventilation so the difference between 
the groups could be due to impaired ventilation. However the C horses were 
actually ventilating more effectively (as determined by PaCO2, see section on 
‘other physiologic parameters’) than the PiNO horses at these time points.  The 
continued decline in PaO2 could also be due to the slow onset of absorption 
atelectasis. Although the high FIO2 could cause absorption atelectasis in both 
groups, the PiNO-mediated redistribution of blood away from the atelectatic 
regions would decrease the impact of those regions on the PaO2.  
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Figure 9. PaO2 and SaO2 from laterally recumbent isoflurane anesthetized horses (Study II). Data 
collection began 45 minutes after anesthesia was induced and continued for 150 minutes. Horses 
indicated with a square received PiNO beginning immediately after data collection at time 45. 
Horses indicated with a circle received the same anesthetic protocol but did not receive PiNO. 
Asterisks indicate significant differences between groups.  Crosses indicate significant difference 
from baseline  (Time 45) measurements. Significance = p<0.05. 
 
 
As expected, PaO2 was very low at baseline in the dorsally recumbent horses 
(Figure 10) and was increased by PiNO administration. The increase in PaO2 
was sustained over a long duration in both Study I and Study II. The efficacy 
of PiNO over a prolonged duration (150 minutes) is important because the 
duration of equine surgical procedures can be quite long.   
 
 
 
 
Figure 10. PaO2 from dorsally recumbent isoflurane anesthetized horses (Study I). Data collection 
began 45 minutes after anesthetic stabilization and continued for a total of 150 minutes. 
a=PiNO20%, b=PiNO30%, c=PiNO43%, d=PiNO60%. PaO2 was significantly higher than 
baseline at all times. Significance = p<0.05. 
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Effects during recovery 
The positive impact of PiNO on oxygenation continued even after the cessation 
of PiNO in both Studies III and IV. Following discontinuation of PiNO while 
the horses were still anesthetized (Study III; Figure 11), the PaO2 and SaO2 
dropped slowly but steadily. The PaO2 did decrease below baseline but not to 
the hypoxemic range. The decrease was probably due to increased perfusion to 
the atelectatic area with a worsening of Qs/Qt following withdrawal of the 
PiNO. These horses, in comparison to the Study IV horses were still receiving 
isoflurane and FiO2 >0.95 so the decline of PaO2 in this group could also be 
due to anesthesia-related hypoventilation, anesthesia-related impairment of 
HPV or a slow development of absorption atelectasis. This study was done as a 
precursor to Study IV to first test the safety of discontinuing PiNO in 
anesthetized horses before moving to a true recovery study where all anesthetic 
support would be discontinued. 
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Figure 11. Gradual decrease in PaO2 following discontinuation of PiNO during isoflurane and 
FiO2 >0.95 oxygen administration (Study III). PiNO was discontinued at Time 0 and data was 
collected for 30 minutes. *=significant difference (p<0.05) from Time 0. 
 
 
The results in Study IV were surprising and exciting.  In Study IV, both the 
PaO2 and the SaO2 were significantly higher in the NO horses than in the C 
horses throughout the entire recovery period (Figure 12) with no decrease over 
time in either group.  This prolongation in oxygenation could have a major 
positive effect on recovery and was unexpected as PaO2 returned to pre-iNO 
baseline within 5 minutes after cessation of PiNO in a previous study 
(Heinonen et al. 2001). The difference could be that the long-duration delivery 
results in a more prolonged effect as both the arterial and venous blood become 
optimally saturated with oxygen. Neither Pv ̄ O2 nor Sv ̄ O2 were reported in 
those studies.  51 
 
 
 
 
Figure 12. PaO2 and SaO2 from horses recovering from isoflurane anesthesia (Study IV). Horses 
indicated with a square received PiNO during anesthesia and horses indicated with a circle 
received the same anesthetic protocol but did not receive PiNO. Asterisks indicate significant 
differences between groups. Significance = p<0.05. 
 
Pv ̄ O2 and Sv ̄ O2 
Venous oxygen parameters may not appear as useful as arterial oxygen 
parameters but, in fact, venous oxygen parameters describe oxygenation at the 
tissue level, where oxygen is required as a metabolic substrate for all 
homeostatic processes. The balance of oxygen delivery (DO2) and oxygen 
uptake (VO2) at the tissue level can be calculated if the Qt is measured, but can 
also be estimated by the Sv ̄ O2. This is an extremely important parameter as 
adequate oxygen delivery to the tissues is the goal of resuscitative therapy yet 
the end-point can be difficult to determine since Qt and ABP do not indicate 
actual DO2. In fact, even with normalization of standard goal directed therapy 
(eg, MAP>70mmHg), DO2 may not be adequate (Scalea et al. 1990, Bannon et 
al. 1995, Pope et al. 2010, Hosking et al. 2011). With the calculation of CaO2, 
DO2 can be determined but this does not determine the utilization of oxygen 
(VO2) at the cellular level and an imbalance of delivery and consumption, 
leading to cellular hypoxia, can exist without being identified. Fortunately, 
Pv ̄ O2 and Sv ̄ O2 can be used to estimate the balance between DO2 and VO2 
(Reinhart and Bloos 2005).  Sv ̄ O2 is commonly utilized in human medicine as 
a prognostic index in critical care patients (Pope et al. 2010). Normal Sv ̄ O2 
values are roughly 70-75% (Hosking et al. 2011) and values below 60-65% 
have been correlated with increased morbidity and mortality in patients with 
certain diseases (Hosking et al. 2011). Hyperoxia (Sv ̄ O2  >90%) is also 
associated with increased mortality, presumably due to decreased tissue 
utilization of oxygen (Pope et al. 2010).  
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In our studies, both Pv ̄ O2 and Sv ̄ O2 were increased during PiNO delivery 
(Studies I and II) and decreased as PiNO effects waned (Studies III and IV). 
The magnitude of the impact of PiNO on venous parameters is most obvious in 
Studies II and IV because the PiNO horses can be compared to the C horses.   
 
Effects during Anesthesia 
In Study II (Figure 13), both Pv ̄ O2 and Sv ̄ O2 were greater in the PiNO horses 
than in the C horses at the last 3 (Sv ̄ O2) or 4(Pv ̄ O2) time points and the Pv ̄ O2 
was greater than baseline at the last two time points. One horse in the C group 
had a Sv ̄ O2 in the upper 60% range at the last 3 time points. 
 
  
 
 
Figure 13. Pv ̄ O2 and Sv ̄ O2 from laterally recumbent isoflurane anesthetized horses (Study II). 
Horses indicated with a square received PiNO during anesthesia and horses indicated with a circle 
received the same anesthetic protocol but did not receive PiNO (C group). Asterisks indicate 
significant differences between groups. Crosses indicate significant difference from baseline 
measurements. Significance = p<0.05. 
 
 
Effects during Recovery 
In the recovery study (Study IV; Figure 14) both Pv ̄ O2 and Sv ̄ O2 decreased 
within the first 10 minutes after cessation of anesthesia and PiNO and then 
stabilized. The decrease was significant from baseline only in the PiNO group.  
However, in spite of significant decrease from baseline, both Pv ̄ O2 and Sv ̄ O2 
were higher in the PiNO horses than in the C horses until the very end of the 
recovery period. Sv ̄ O2 average values in the PiNO horses were in the 60% 
range at T10-30. In the C horses Sv ̄ O2 average was in the 60% range from T2-
8 and in the 50% range from T10-30 (lowest value average 7 kPa [53 mmHg] 
at T25), meaning that the Sv ̄ O2 was in the possible critical range in the C 
horses from the time that 100% oxygen was discontinued. The highest Sv ̄ O2 in 
the C horses (average 8.3 kPa [62 mmHg]) occurred immediately after 53 
 
cessation of FiO2 0.95 oxygen and anesthesia, whereas the lowest Sv ̄ O2 in the 
PiNO horses (average 8.4 kPa [63 mmHg]) occurred at T30 when the horses 
were struggling to stand.  
 
 
 
Figure 14. Pv ̄ O2 and Sv ̄ O2 from horses recovering from isoflurane anesthesia (Study IV). Horses 
indicated with a square received PiNO during anesthesia and horses indicated with a circle did not 
receive PiNO (C group). Asterisks indicate significant differences between groups. Crosses 
indicate significant difference from baseline measurements. Significance = p<0.05. 
 
 
General comments 
Decreased Pv ̄ O2 and Sv ̄ O2 is caused by: 1) decreased DO2 due to ventilatory 
(ie, hypoxemia leading to decreased PaO2 and SaO2) or cardiovascular (eg, 
decreased Qt, hemoglobinemia, anemia, hypovolemia, hemorrhage or shock) 
factors, and/or 2) increased VO2 due to factors that increase oxygen 
consumption (eg, hypermetabolism, hyperthermia, shivering, pain, movement 
or seizures). By analyzing each of these components, the cause of the 
differences between the PiNO and C horses can be determined. First, the Qt in 
horses in Study II did not change during the study. In Study IV, due to the 
waning effects of inhalant gases and the beginning of spontaneous movement, 
we would expect the cardiac output to increase, not decrease, during recovery 
from anesthesia. Second, none of the horses in either group were 
hypermetabolic, hemoglobinemic, anemic, hypovolemic, hemorrhaging, in 
shock, hyperthermic, in pain or seizuring.  Thus, the significant differences in 
the Sv ̄ O2 between the two groups of horses were due to the fact that the C 
horses were more hypoxemic than the PiNO horses throughout the entire study 
period in both Studies II and IV. The decline of Sv ̄ O2 that occurred in Study IV 
regardless of the initial oxygenation status, was most likely due to increased 
VO2 due to the initial shivering that the horses were experiencing in early 
recovery followed by movement and standing in mid to late recovery. All 54 
 
horses had minor movements (lifting the head or moving a limb) by T10-15 
and all had attempted to attain sternal recumbency or to stand by T 20.  
 
 
Although the prognostic value of Sv ̄ O2 for morbidity and mortality has not 
been established in the horse and all of these horses recovered without incident, 
these were healthy horses and the outcome could potentially be different in 
unhealthy horses.  Horses anesthetized for surgical correction of colic had a 
greater negative oxygen balance and decreased muscle oxygenation than 
healthy horses (Edner et al. 2007). Since decreased tissue oxygen, or ischemia, 
is implicated in post-anesthetic myopathy and neuropathy (Wagner 2008a), 
improved tissue oxygenation during the recovery period could potentially 
decrease the incidence of these morbidities and perhaps improve the safety of 
equine anesthesia.   
Because lactate is produced during anaerobic metabolism, plasma lactate 
concentrations can also be used to evaluate tissue oxygen delivery. Increased 
lactate is a predictor of morbidity and mortality in both humans (Bakker and de 
Lima 2004, Mikkelsen et al. 2009) and horses (Tennent-Brown et al. 2010, 
McCoy et al. 2011). Measurement of lactate in our studies would have allowed 
an interesting comparison to Sv ̄ O2.  
 
Qs/Qt   
The PiNO-induced decrease in Qs/Qt was used as a major determinant of 
improved pulmonary function in our studies because Qs/Qt, as calculated by 
the classic Berggren equation (Berggren 1942), is widely considered to be the 
‘gold standard’ of pulmonary function calculations (Nelson 1993). As stated in 
the introduction, Qs/Qt is the ratio of the portion of blood shunted from the 
venous circulation to the arterial circulation without being oxygenated (Qs) to 
the total blood flow (Qt).  In addition to the atelectasis that causes 
intrapulmonary shunt in horses, intrapulmonary shunt can also be caused by 
diffusion impairment and by blood flow to areas of consolidation (eg, tumors 
or abscesses).  A normal intrapulmonary shunt in humans is <5%  (Johnson 
2004) and this fits with the shunt identified in standing horses (1%) 
(Hedenstierna et al. 1987). A shunt of 5-15% would be considered mild, 15-
30% would be ‘major’ and >30% would be ‘severe’ in humans (Johnson 
2004). If Qs/Qt is >50%, the PaO2 is not likely to improve with oxygen 
therapy. As can be seen by our data, anesthetized horses commonly develop 
Qs/Qt that would be considered ‘severe’ for humans, further emphasizing the 
dramatic adverse effects of anesthesia on equine respiratory physiology. 
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Effects during anesthesia 
PiNO delivery decreased Qs/Qt in all studies. In dorsally recumbent horses 
(Study I; Figure 15), the Qs/Qt decreased with the first dose of PiNO 
(PiNO20%) from 32% at baseline and remained at an average of 25% 
throughout the entire duration of the 2.5 hour study.  This is lower than the 
Qs/Qt that often occurs in dorsally recumbent horses and the horses in dorsal 
recumbency in V (MIGET) were more representative with a Qs/Qt of just over 
50% at baseline. In spite of the magnitude of the Qs/Qt, the horses did respond 
to treatment and Qs/Qt decreased to just over 30% during PiNO administration. 
The Qs/Qt increased back to baseline 30 minutes after PiNO cessation.  
 
 
 
 
Figure 15. Qs/Qt from dorsally recumbent isoflurane anesthetized horses (Study I). a=PiNO20%, 
b=PiNO30%, c=PiNO45%, d=PiNO60%. PaO2 was significantly higher than baseline at all times. 
Significance = p<0.05. 
 
In laterally recumbent horses (Study II; Figure 16), Qs/Qt was again 
decreased with the first dose of PiNO (PiNO30%) and was significantly lower 
in the PiNO than the C horses at all times throughout the duration of the study 
except at baseline. However, the Qs/Qt data were more variable in this study 
than in Study I, which kept the values from reaching a statistical difference 
from baseline values. The Qs/Qt was in the 30% range from T45-T75 and 40% 
range from T90-T150 in the C horses and in the 20% range in the PiNO horses 
at all times. 56 
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Figure 16. Qs/Qt from laterally recumbent isoflurane anesthetized horses (Study II). Horses 
indicated with a square received PiNO beginning immediately after data collection at time 45. 
Horses indicated with a circle received the same anesthetic protocol but did not receive PiNO. 
Asterisks indicate significant differences between groups.  Significance = p<0.05. 
 
 
Recovery effects 
The improvement in pulmonary function was sustained in recovery (Study IV; 
Figure 17) and the Qs/Qt in the PiNO horses (range 13-17% at various time 
points) was lower than the Qs/Qt in the C horses (range 30-48% at various time 
points) throughout the entire recovery period. The Qs/Qt of the control group 
slowly decreased but did remain significantly greater than the PiNO group. The 
decrease was potentially due to improved ventilation and re-expansion of 
alveoli with low VA/Q or to the waning effects of the high intra-operative FiO2 
with a subsequent decrease of the degree of absorption atelectasis.  The 
prolonged effect on Qs/Qt is a major finding in our work since Qs/Qt is a 
marker of pulmonary function. If pulmonary function is improved throughout 
recovery, horses would be less likely to become hypoxemic, even if recovery 
was prolonged. The improvement in pulmonary function could be an indication 
to administer PiNO even in horses that are only marginally hypoxemic.  
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Figure 17. Qs/Qt (shunt fraction) from horses recovering from isoflurane anesthesia (Study IV). 
Horses indicated with a square received PiNO during anesthesia and horses indicated with a circle 
received the same anesthetic protocol but did not receive PiNO. Asterisks indicate significant 
differences between groups. Crosses indicate significant difference from baseline measurements. 
Significance = p<0.05. 
 
 
However, in Study III (Figure 18), the Qs/Qt gradually increased to a point that 
was significantly higher than baseline (mean 40%) but not abnormally high for 
dorsally recumbent horses. These horses were still anesthetized with isoflurane 
and FiO2 > 0.95 oxygen so the increase maybe due to a gradual return to a high 
percentage of VA/Q mismatch or to the continued effect of a high FiO2 on 
absorption atelectasis, or both.  
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Figure 18.  Gradual increase in Qs/Qt (shunt fraction) in horses anesthetized with isoflurane and 
oxygen following discontinuation of PiNO during anesthesia (Study III). PiNO was discontinued 
at Time 0 and data was collected for 30 minutes. *=significant difference (p<0.05) from Time 0. 
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General comments 
Although it is considered the gold standard for Qs/Qt calculations, there are 
some limitations to the Berggren shunt equation.  Primarily, the formula does 
not allow a differentiation between intrapulmonary and extrapulmonary 
shunting since venous admixture from the Thebesian and pulmonary veins is 
included in the Qs/Qt value. Also, the Berggren equation does not allow 
differentiation of Qs/Qt from very low VA/Q regions nor does it allow the 
identification of diffusion impairment. Differentiation of various causes of 
Qs/Qt can be important in determining the mechanism of action of drugs or 
techniques designed to improve pulmonary function, such as the delivery of 
PiNO. Finally, the equation is based on some measurements (arterial and 
mixed venous blood gas values) but also on some calculations (pulmonary 
capillary oxygen content) and errors in calculation or errors in assumptions 
(like PaCO2=PACO2) can lead to errors in Qs/Qt values. The most precise way 
to determine true intrapulmonary Qs/Qt is with the MIGET (Wagner 2008b). 
 
P(A-a)O2    
Shunt fraction can also be estimated in clinical practice by a variety of oxygen 
tension indices that use a comparison of the driving pressure (FiO2 or PAO2) 
for diffusion of oxygen into the pulmonary capillary blood to the actual PaO2  
(Johnson 2004). Indices include P(A-a)O2, PaO2/FiO2, PaO2/PAO2 and 
others. Oxygen tension indices are often used to assess pulmonary function in 
clinical patients since the indices can be calculated with data obtained from an 
arterial blood gas (PaO2 and PaCO2) with no need to collect mixed venous 
blood as is required to calculate Qs/Qt.  In Studies II, III and IV we calculated 
P(A-a)O2 as a marker of pulmonary function. PiNO delivery decreased P(A-
a)O2 in all studies and cessation of PiNO resulted in a slow increase in the P(A-
a)O2 values. In studies II and IV the P(A-a)O2 was larger in the C horses than 
in the PiNO horses. Thus, the P(A-a)O2 values in our study paralleled the 
Qs/Qt values, as found in other equine studies (Marntell et al. 2005b). 
However, values for P(A-a)O2  can be skewed by factors other than pulmonary 
function, including the FiO2 and the PaCO2 . In our studies, the horses were on 
various FIO2 (1 in Studies II and III; roughly 0.3 in Study IV)and increased 
FiO2 causes an increased P(A-a)O2  that seems to exceed the actual increase in 
Qs/Qt (Staffieri et al. 2009, Johnson 2004). Also, the horses were hypercarbic 
in many of the studies and hypercarbia will falsely decrease the value for P(A-
a)O2 due to a lower calculated PAO2. Finally, the true Qs/Qt value can be 
skewed because PaCO2 is used as equivalent to PACO2, and this assumption is 
not always true (Robertson and Hlastala 1977). P(A-a)O2 has failed to correlate 
to Qs/Qt in equine studies. For instance, P(A-a)O2 significantly increased 59 
 
following detomidine sedation in standing horses (0.5±0.4 presedation, 2.2±0.7 
postsedation) but the change in Qs/Qt was insignificant (1.1 ± 0.3 presedation, 
1.3±0.4 postsedation) (Nyman et al. 2009). Therefore, we based the 
conclusions regarding the magnitude of shunt in our studies on Qs/Qt.  
 
 Ventilation-perfusion distribution measured by MIGET 
The gold-standard for measuring intrapulmonary Qs/Qt and VA/Q matching is 
the MIGET, which uses the solubility of six inert gases to determine the VA/Q 
relationships from Qs/Qt (VA/Q=0) to VD/VT (VA/Q=infinity). A major 
advantage of Qs/Qt determined with MIGET is that the extrapulmonary venous 
admixture is not included in the Qs/Qt values and the percentage of areas of 
low VA/Q can be differentiated from Qs/Qt (Wagner 2008b). MIGET was first 
described in the 1970s by Wagner (Wagner 2008b) and has since been used in 
a variety of species (Frans et al. 1993, Schmekel et al. 1994, Batchinsky et al. 
2006, Strang et al. 2010) to determine VA/Q matching. MIGET was adapted for 
the horse in 1987 by Hedensternia & Nyman (Hedenstierna et al. 1987) and 
was used to evaluate pulmonary function in conscious standing horses. In that 
study, Qs/Qt was 1.2+/-0.4% and logSDQ was 0.41+0.05. The RSS was an 
average of 4.9. MIGET has also been used to determine the VA/Q relationships 
in horses:  anesthetized with halothane (Nyman and Hedenstierna 1989); 
sedated with detomidine and butorphanol (Nyman et al. 2009); sedated with 
romifidine and butorphanol with or without acepromazine followed by 
tiletamine-zolazepam anaesthesia (Marntell et al. 2005a); conscious, sedated 
and anesthetized breathing either FiO2 of 0.21 or >0.95 (Marntell et al. 2005b); 
anesthetized receiving clenbuterol (Dodam et al. 1993); during heavy exercise 
(Wagner et al. 1989, Seaman et al. 1995) and prolonged exercise (Hopkins et 
al. 1998); breathing helium during exercise (Erickson et al. 1994); with red cell 
hypervolemia (Funkquist et al. 1999); with chronic (Nyman et al. 1991) or 
mild (Nyman et al. 1999) bronchiolitis; and with a history of Rhodococcus equi 
pneumonia as foals during high intensity exercise as adults (Funkquist et al. 
2002). 
 
Other values of particular interest obtained from the MIGET include the 
standard deviation of the logarithmic distribution of perfusion (LogSDQ) and 
the standard deviation of the logarithmic distribution of ventilation (LogSDV), 
which are dimensionless numbers that describes the degree of dispersion or 
VA/Q match/mismatch. In humans, normal logSD values range 0.4–0.6, 
moderate disease may cause an increase 1.0 while severe disease would result 
in logSD of 1.5–2.5 (Wagner 2008b). The residual square of sums (RSS) which 
describes the ‘goodness of fit’ or precision of the model and is a quality control 60 
 
assessment. Acceptable RSS values are <6. MIGET was used in dorsally 
recumbent horses receiving PiNO for 5 minute intervals (Heinonen et al. 
2001). In that study Qs/Qt was 32±2, 22±2, and 30±3 in spontaneously 
breathing horses before, during and 15 minutes after PiNO administration and 
26±4, 19±4 and 25±4 in horses with IPPV at the same time periods. LogSDQ  
prePiNO was 0.46-1.15 in individual horses and decreased to 0.37-0.79 during 
PiNO (indicating more efficient matching of VA/Q) with a return to baseline 
postPiNO. RSS for this study was 0.3-5.6. These data are comparable to the 
data obtained in our studies. MIGET was used in Studies II (lateral 
recumbency) and V (dorsal recumbency and scintigraphy). Results from Study 
V (MIGET) will be discussed in the ‘mechanism of action’ section.  In Study II 
(MIGET) (Table 3; Figure 19), PaO2 increased while Qs/Qt and logSDQ 
decreased in all horses with PiNO30%. In horses 1 and 2, PiNO60% caused 
minimal changes from PiNO30%. As previously mentioned, in horse 3, 
PiNO60% caused deterioration in PaO2 compared to PiNO30% and values 
returned towards baseline values. The marked improvement in arterial 
oxygenation during PiNO in horses 1 and 2 was due to an evident reduction of 
Qs/Qt with minimal impact on low VA/Q areas. Compared to baseline, Qs/Qt 
decreased in all three horses during PiNO30% and was lower in two horses and 
higher in one horse during PiNO60%. Log SDQ decreased during PiNO and 
the RSS of all studies indicated a good fit of the data to the predicted data.  
 
 
  Study II (MIGET)  Study V (MIGET) 
Time 
Variable 
PrePiNO PiNO30% PiNO60% PrePiNO  PiNO  PostPiNO 
Log SDQ  0.79±0.10  0.70±0.07  0.66±0.02  1.00±0.14  0.83±0.13  0.98±0.09 
Qs/Qt%  39±8  30±5  33±6  51±5  32±6  51±8 
PaO2 kPa  18.7±9.0  30.4±4.6  27.7±0.4  6.7±0.8  16.8±6.3  8.9±1.9 
PaO2 
mmHg  140±67  228±35  208±3 
50±6  126±47  67±15 
 
Table 3. Physiologic data excerpted from Study II (MIGET) and Study V (MIGET). 
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Figure 19. Ventilation-perfusion distribution in one horse (Study II (MIGET)). Data from one 
horse is presented as an example of the changes induced by PiNO. The ventilation-perfusion 
distribution (VA/Q) presented as a log scale and the ventilation and perfusion in L min
-1 as open 
and closed circles, respectively.  
 
 
One limitation of the MIGET is that it can be used to determine the degree of 
matching of ventilation with perfusion but it cannot provide information on the 
actual localization of the changes in perfusion (Wagner 2008b), which will be 
discussed in a later section. 
 
Pulmonary arterial pressure (PAP) 
A primary goal of iNO therapy in humans is to improve oxygenation by 
decreasing the PAP in patients with pulmonary arterial hypertension (PAH) 
(Ichinose et al., 2004, Griffiths and Evans, 2005, Bloch et al., 2007, Creagh-
Brown et al., 2009). Inhaled NO can relieve PAH in horses, as evidenced by 
the fact that iNO decreased PAP in exercising horses with pulmonary 
hypertension (Mills et al. 1996, Kindig et al. 2001). However, PAP was 
measured in Studies II and horses in those studies did not have lower PAP 
during PiNO administration as would have been expected when considering 
the mechanism of action of iNO (Table 3). PAP did slowly increase in Study 
III and this will be further discussed in the safety section. Failure of PiNO to 
decrease PAP in horses also occurred in earlier studies from our laboratory 
(Heinonen et al. 2001, Heinonen et al. 2002).  
Although no significant changes in overall PAP were detected, the lung is a 
very heterogeneous organ and VA/Q matching can vary in different regions of 
the lung. The inability to detect a global change does not exclude the fact that 
regional differences might occur.  Also, the well-ventilated areas of the lung 
were poorly perfused but not necessarily hypertensive in our studies so a 
reduction of PAP was not necessary for improved gas exchange. In healthy 
human volunteers, breathing endogenous (nasal) or exogenous iNO, the iNO 62 
 
caused a redistribution of pulmonary perfusion (Sanchez Crespo et al. 2010). 
Because these patients were probably not afflicted with pulmonary 
hypertension (although PAP was not measured), the redistribution of the blood 
flow represents a movement of blood in response to vasodilation in well 
ventilated areas with a subsequent improvement in VA/Q matching rather than 
a decrease in PAP.   
Redistribution of flow is an important concept for the use of PiNO in 
anesthetized horses. Rather than being used to improve oxygenation by 
reduction of PAP, in anesthetized horses PiNO would be used to improve 
oxygenation through redistribution of blood flow from low to high VA/Q 
regions in patients that are likely to have normal pulmonary blood pressures. 
This may further add to the safety of PiNO in horses because it is possible that 
a lower dose of iNO is required to improve oxygenation than is required to 
relieve PAH (Griffiths and Evans 2005). Another potential reason for the lack 
of decreased PAP during PiNO in our horses is that anesthesia may have 
caused a decrease PAP, thereby masking any increase that might have been 
detectable in the absence of anesthesia. Finally, there is a potential that we are 
evaluating the wrong parameter. In healthy conscious human volunteers, 
blockade of endogenous NO by L-NG-monomethyl Arginine citrate (L-
NMMA) caused an increase in pulmonary vascular resistance by almost 40% 
but no change in PAP because of a concurrent decrease in Qt (Stamler et al. 
1994). Although Qt remained steady in our horses, the Qt in anesthetized 
horses is lower than the Qt in conscious horses and this could mask or blunt 
any changes in pulmonary vascular resistance (PVR). A final possibility for the 
lack of change in PAP is that pulmonary hypertension is mediated by HPV and 
there are reasons that alterations in HPV might have affected our results. HPV 
is discussed in detail in a subsequent section.  
 
Study II  PAP  PrePiNO 
(T45) 
PAP range (lowest to highest) during 
PiNO 
PiNO horses  26.8± 8.8  23.7± 7.6 (T105) to 25.7± 7.1 (T60)  
Control horses  26.7± 4.4  23.3± 7.5 (T60) to 28.0± 6.5 (T120) 
 
Table 4. Pulmonary artery pressure in Study II (horses anesthetized in lateral recumbency with 
isoflurane and oxygen without (C) or with PiNO). 
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Other physiologic variables  
 
Cardiovascular data 
HR was measured in all studies and ABP and Qt were measured in all studies 
except Study IV. HR was slightly but significantly lower during the iNO 
treatment in Study I, slightly higher PostPiNO than PrePiNO in Study V, but 
was not different between groups or over time in Study II. ABP increased in 
the first 30 minutes of data collection in Studies I and II in all groups. Qt also 
increased slightly over time in Study I but did not change and was not different 
between groups in Study II. Because the ABP increased in the C group as well 
as the PiNO groups, we do not attribute the increase to PiNO-mediated 
systemic changes but rather to normal adaptation to inhalant anesthesia as has 
been previously described (Steffey et al. 1987) or to hypercarbia-mediated 
cardiovascular stimulation (see respiratory data below). In Study III, the HR 
increased slowly over time but the ABP did not change so presumably the SV 
decreased. The increase in the HR may have been in response to the declining 
PaO2. In Study IV, there was no difference in HR between groups. ABP, 
MPAP and Qt were not measured during recovery due to the danger of having 
the equipment in the recovery stall as the horse regained consciousness. 
A limitation that could affect clinical use is that, at various times, horses in 
all studies were hypotensive and the hypotension was not treated. Hypotension, 
which can alter PaO2 by decreasing pulmonary blood flow, is generally treated 
in anesthetized horses by the administration of positive inotropic drugs, like 
dobutamine. However, the administration of dobutamine also increases Qs/Qt, 
possibly due to increased blood flow in dependent atelectatic lung areas 
(Swanson and Muir 1986). Hypotension would, by necessity, be treated in 
clinical patients and treatment could potentially decrease the effectiveness of 
PiNO.  
  
Respiratory data 
During anesthesia (Studies I, II and V), all horses had varying degrees of 
respiratory depression as indicated by increased PaCO2  and respiratory 
acidosis. There were no statistically significant differences in RR or TV in 
either Study I or II but the minor differences that did occur contributed to the 
hypercarbia and respiratory acidosis. Both PaCO2 and pHa were significantly 
different in the PiNO group than the C group at time points towards the end of 
anaesthesia in Study II. Horses in both groups experienced anesthesia-induced 
respiratory depression and suppression of the hypercarbic respiratory drive. 
However, we are unclear as to the mechanism of the difference between the 
PiNO and C groups. The most likely cause is increased ventilation due to 64 
 
hypoxemic respiratory drive in the C horses, however, hypoxemic respiratory 
drive reportedly does not occur until the PaO2 is <8 kPa (60 mmHg) and the 
lowest PaO2 in the C group was approximately 9.2 kPa (69 mmHg) at T150.  
However, this value for initiation of hypoxemic drive is for humans and the 
value for horses is unknown, so perhaps hypoxemic respiratory drive occurs at 
a higher PaO2 in horses. In Study V, the RR was rapid in one horse and this is 
discussed in the ‘mechanism of action’ section. In study III, the RR rate did not 
change but the TV increased at the final time points, causing a decrease in the 
PaCO2. The increase in the TV may have been in response to the declining 
PaO2.  
In Study IV, no differences in RR occurred over time or between groups. 
The RR increased quickly after cessation of anesthesia (from 3-5 breaths/min 
at the end of anesthesia to 11-13 breaths/min in recovery) and remained stable 
throughout recovery in both groups. PaCO2 was higher at Time 2 than at any 
other time point in both groups of horses but this difference was only 
significant in the PiNO horses and there were no other differences within or 
between groups over time. The horses were mildly hypercarbic and acidemic 
throughout recovery but the PaCO2 was lower and the pHa was higher when 
compared to values measured during anesthesia in studies I and II. These 
results are due to the increased RR, which is an expected response in horses 
recovering from the respiratory-depressant effects of anesthesia.  
The fact that hypercarbia was fairly common but was not treated could be a 
limitation that might affect clinical use of PiNO. Hypercarbia, which can alter 
gas exchange as described by the alveolar gas equation, is generally treated 
using mechanical ventilation. However, as stated in the introduction, positive 
pressure ventilation has been shown to decrease total blood flow and to alter 
VA/Q and Qs/Qt, thus hypercarbia was not treated in our study. Hypercarbia 
would, by necessity, be treated in clinical patients and treatment could 
potentially decrease the effectiveness of PiNO.  
4.2  Preparing for Clinical Use: Safety of PiNO 
Discontinuation of PiNO pulsed in the first 30-45% of the inhalation phase of 
the breath did not cause a rapid and/or dangerous ‘rebound’ increase of PAP or 
Qs/Qt nor a decrease of PaO2 in anesthetized horses (Study III) or horses 
recovering from anesthesia (Study IV).  Plasma concentrations of ET-1 did not 
increase during (Studies II, III and V) or after (Study IV) anesthesia.  NO did 
not accumulate in the anesthesia breathing circuit (Studies I, II (MIGET), III) 
and N2O was not detected (Study III). Thus, PiNO should be considered safe to 
deliver during isoflurane anesthesia in healthy horses. 65 
 
4.2.1 ‘Rebound  Effect’ 
As stated in the introduction, withdrawal of iNO can produce a precipitous 
decrease in PaO2 with a concurrent increase in Qs/Qt and PAP that is 
potentially mediated by an increase of circulating ET-1 concentrations -1) 
(Chen et al. 2001, McMullan et al. 2001, Wedgwood et al. 2001, Pearl et al. 
2002). Our results indicate that, following the withdrawal of PiNO, an ET-
induced rebound effect does not develop in healthy isoflurane-anesthetized 
horses.  
 
Indices of rebound 
We used potential changes in oxygenation, Qs/Qt, PAP and ET-1 
concentrations to monitor for a rebound effect. 
 
Oxygenation, Qs/Qt and PAP 
The lack of a rapid decrease in PaO2 or SaO2 (Figure 6) or a rapid increase in 
Qs/Qt (Figures 12 and 13, above) after the discontinuation of PiNO in horses 
still receiving isoflurane and FiO2 > 0.95  (Study III) suggested that a rebound 
effect would not occur following PiNO discontinuation in a true anesthesia 
recovery situation. Study III was completed before attempting a true recovery 
situation because horses recovering from anesthesia can be quite dangerous 
and, if a rebound effect following PiNO discontinuation occurred, the horse 
could be hard to treat. In fact, not only did a rebound effect fail to occur 
following discontinuation of PiNO, isoflurane and FiO2 > 0.95 in Study IV, 
PiNO delivered during anesthesia caused a prolonged beneficial effect that 
allowed both arterial and venous oxygenation (Figures 5 and 8)  to remain 
higher and Qs/Qt (Figure 11) to remain lower in the PiNO group than the C 
group throughout most of recovery. The reason for the prolonged effect on 
oxygenation is unclear but could potentially be related to distant effects of 
PiNO (Hambraeus-Jonzon et al. 2001) or to the fact that the baseline 
oxygenation was very high, prolonging time to desaturation (Edmark et al. 
2003). 
One limitation is that PAP was not measured in Study IV because it was 
dangerous to have the monitoring equipment in the recovery stall as the horses 
were regaining consciousness. However, PAP measured in Study III slowly 
increased  (baseline 14±3; range following discontinuation of PiNO 14±1 to 
17±1)  but was never significantly different from baseline nor higher than 
expected for horses under anesthesia and a slow, minor change does not fit the 
definition of rebound. Furthermore, decreasing oxygenation and increasing 
shunt are also hallmarks of a rebound effect and neither of these phenomena 
occurred in the horses in Study IV. 66 
 
 
ET-1 
ET-1, an endogenous endothelium-derived peptide is an extremely potent 
vasoconstrictor. Like NO, ET-1 acts in close proximity to its site of synthesis. 
Also like NO, ET-1 may contribute to basal pulmonary vascular tone (Johnson 
et al. 2002). Increased ET-1 concentrations cause pulmonary vasoconstriction 
with subsequent PAH,  and increased ET-1 is a component of the pulmonary 
vasoconstrictive response to hypoxia (ie, HPV), although whether it is a 
primary component or a supporting component is unknown (Moudgil, 
Michelakis and Archer 2005, Sylvester et al. 2012)(see more on HPV in the 
next section). Increased ET-1 may also be a component of the rebound 
phenomena and ET-1 was chosen as a marker for rebound because 
concentrations of the peptide increase during iNO administration (Chen et al., 
2001, McMullan et al., 2001, Wedgwood et al., 2001, Pearl et al., 2002). 
Although the exact mechanism of the rebound effect is unknown, the increase 
in ET-1 and the concomitant decrease in NOS activity are likely contributors. 
As in other species, ET-1 is a potent vasoconstrictor in the pulmonary vessels 
in horses (Benamou et al. 2003, Benamou, Marlin and Lekeux 2001) and ET-1 
concentrations increase in horses known to have diseases that cause pulmonary 
vasoconstriction, like recurrent airway obstruction (Benamou et al. 1998, Costa 
et al. 2009).  
In our studies, plasma ET-1 concentrations did not increase either during 
(Studies II and V, Table 5) or after (Studies III and V, Table 5 and Study IV 
Figure14) PiNO administration.  The ET-1 data from Study IV are quite 
interesting because the C group of horses, which were more hypoxemic than 
the PiNO group at all times, also had higher ET-1 concentrations at all times, 
although there was considerable variability in the data and significance was 
only reached at T2, T20 and T25.  
 
 
 Study II       T45    T150 
ET-1 PiNO picomol/mL  6.62± 1.89    7.82± 1.16 
ET-1 C picomol/mL  6.71± 2.04    7.38± 2.92 
Study III  0 mins (T0)  10 mins  30 mins 
ET-1 picomol/mL  4.40 ± 0.46  4.62 ±0.42  5.04 ±0.50 
Study V  PrePiNO  PiNO  PostPiNO 
ET-1 picomol/mL  5.59±0.51  7.65±1.91  5.49±2.43 
Table 5. ET-1 concentrations during isoflurane anesthesia with or without PiNO (Study II), 
following cessation of PiNO in anesthetized horses (Study III) and before, during and after PiNO 
administration for 15 minutes (Study V). Data are presented as mean±SEM.  67 
 
Although, ET-1 increases during PiNO, ET-1 also increases in response to both 
acute and chronic hypoxia (Ferri et al. 1995, Trakada and Spiropoulos 2001, 
Talbot et al. 2008). It is possible that the low doses of PiNO produced by 
pulse-delivery are too low to increase ET-1 concentrations, while the 
hypoxemia experienced by the C horses did increase ET-1 concentrations. A 
reduction of ET-1 concentration also occurs during acute lung injury, 
potentially because of anti-inflammatory properties of iNO (Busch et al. 2006). 
However, our horses were healthy and this is unlikely to be the case in our 
studies. Because PiNO has not previously been studied in-depth in anesthetized 
horses, we cannot rule out the fact that ET-1 may not increase in response to 
iNO in this species. 
 
 
Figure 20. Plasma ET-1 concentrations from horses recovering from isoflurane anesthesia (Study 
IV). Horses indicated with a square received PiNO during anesthesia and horses indicated with a 
circle received the same anesthetic protocol but did not receive PiNO. Asterisks indicate 
significant differences between groups. Significance = p<0.05.  
 
 
The use of ET-1 concentrations as a marker for the rebound effect could 
also be a limitation of our study. Although the fact that the lack of adverse 
changes in arterial and venous oxygenation and Qs/Qt indicate that a rebound 
did not occur, we may be looking for the wrong marker as ET-1 may not be 
responsible for producing hypoxic pulmonary hypertension (Johnson et al. 
2002) or a rebound effect in all species. Also, ET-1 can be difficult to 
consistently detect, even after stimuli that should cause an increase in 
circulating ET-1(Morganti et al. 2000). Although hypoxia does seem to 
consistently produce an increase in ET-1 (Morganti et al. 2000), the difficulty 
in detection could increase the variability in results and could explain some of 
the inconsistent values that occurred in our study. Also, the assay that we used 68 
 
has not been validated for the horse, thus our data can be compared within our 
study and but may be invalid when compared to other studies.  
Why no rebound? 
When compared to other studies, there are several components of our studies 
that might explain the lack of a rebound effect. The impact of ET-1 and 
endogenous NO have already been discussed. The other most likely 
components are the delivery method of the iNO, species studied, anesthetic 
drugs used, and health of study animals 
 
PiNO delivery method 
As stated above, there is the potential that the low dose of iNO delivered by 
pulse does not induce an increase in ET-1 concentrations and thus might not 
induce a rebound effect.  
 
Horses and hypoxic pulmonary vasoconstriction (HPV) 
In response to hypoxemia, systemic arteries dilate but pulmonary arteries 
constrict in a phenomena termed ‘hypoxic pulmonary vasoconstriction’ (HPV). 
The mechanism of HPV is not completely elucidated but it begins with low 
alveolar oxygen tension (low PAO2) and ends with contraction of the 
pulmonary arterial smooth muscle cells located primarily in resistance arteries 
of <200 mm (Moudgil et al. 2005). HPV is a locally-produced, endothelium-
dependent protective mechanism designed to limit blood flow to hypoxemic 
areas of the lung in order to optimize VA/Q matching and decrease the impact 
of hypoxemic lung regions on PaO2 (Nagendran et al. 2006).  
The constrictive response of the pulmonary vasculature to hypoxia is highly 
variable among species and marked differences occur in both the magnitude of 
the HPV response and the oxygen level required to provoke the response 
(Peake et al. 1981). The horse appears to elicit a fairly weak HPV response, 
although not as weak as that of the dog (Elliott et al. 1991). HPV occurs in 
equine and bovine isolated pulmonary arterial rings but the HPV response in 
equine pulmonary vessels is approximately 33% less than the response in 
bovine vessels (MacEachern et al. 2004). In the intact animal, ponies develop 
only moderate HPV yet pigs develop profound HPV (Elliott et al. 1991). In 
one-lung ventilation models of hypoxemia, the pig develops profound HPV 
(Hambraeus-Jonzon et al. 2001) while the horse fails to develop any HPV 
(Lerche 2006) response. The cause(s) of the species differences are unknown 
and, in a 154 page review of HPV, the author offered only this theory, ‘The 
mechanisms underlying species variability in HPV are unknown; however, the 
ubiquity of the response and observations that differences are quantitative 
rather than qualitative argue against variability in the fundamental mechanisms 69 
 
of HPV. More likely, species differences result from variability in mechanisms 
that modulate HPV (Sylvester et al. 2012). 
Among other species, the rebound phenomena has been reported in humans 
(Ichinose et al. 2004), pigs (Chen et al. 2001) and sheep (Black et al. 1999, 
Ross et al. 2005). Pigs produce a profound HPV response and can experience a 
profound rebound effect. The HPV response in horses is less than that of the 
pig, and horses in our study did not have a rebound effect.  To our knowledge, 
the HPV response in humans has not been directly compared with that of 
horses or pigs, but results of research in altitude-induced HPV suggest that 
there is great variability among individuals  (Naeije 1997), which could further 
contribute to the fact that some humans respond to NO inhalation and some do 
not, and some develop rebound and some do not. So perhaps there is a species-
specific intrinsic degree of vasoreactivity that predisposes each species to an 
inherent HPV response that is mirrored by an inherent rebound effect. 
However, sheep do not fit this theory as sheep have a minimal HPV response 
(Sylvester et al. 2012) and yet can have a profound rebound response (Black et 
al. 1999, Ross et al. 2005). Because the HPV response is very species-specific 
and because the species specificity cannot be explained, any direct species-
species comparisons regarding HPV and pulmonary function in response to 
hypoxia is difficult. 
 
Drugs used for Anesthesia   
The sedatives and general anesthetic drugs used in our studies could also have 
affected our results. Horses were anesthetized with isoflurane and inhalant 
anesthetic drugs are known to affect HPV. Inhalant anesthetic drugs generally 
inhibit the HPV response whereas injectable anesthetic drugs may inhibit, 
maintain, or even potentiate the HPV response (Nagendran et al. 2006). 
However, a rebound response has been detected in conscious and anesthetized 
humans, conscious and anesthetized sheep and anesthetized pigs. Thus, 
because of the wide variety of anesthetics used and the inclusion of conscious 
subjects in clinical treatment and research trials, it is unlikely that the rebound 
effect or lack of a rebound effect could be totally attributed to the anesthetic 
protocol. Nevertheless, it could be argued that the inhalant anesthetic drug used 
in the present study blunted the HPV response, thereby decreasing the degree 
of pulmonary vasoconstriction and minimizing the effect of NO inhalation 
among the study horses. This would indeed decrease the likelihood of a rapid 
rebound response following cessation of NO inhalation but would also have 
limited the initial response to NO. Although the horses in our study responded 
to inhalation of NO, whether the response would have been greater if 
isoflurane had not been used cannot be determined.  70 
 
Finally, the variety of effects caused by different anesthetic drugs could 
explain the fact that halothane-anesthetized horses failed to respond to NO 
inhalation (Young et al. 1999) and yet isoflurane anesthetized horses in our 
study did respond to NO inhalation. Whether or not the anesthetic drugs 
blunted the response to PiNO and the lack of a rebound effect is actually only 
important as a point of discussion and not as a limitation since the goal of our 
studies is to find a means to relieve hypoxemia in anesthetized horses. The 
anesthetic protocol that we used is a standard protocol used in clinical cases. 
Interestingly, different anesthetic protocols may affect endogenous NO 
differently, as inhalant anesthesia with halothane caused a significantly lower 
production of exhaled nitric oxide than romifidine-guaifenesin-ketamine 
caused (Marlin et al. 2001). This could contribute to the greater impairment of 
pulmonary function by inhalant anesthesia when compared to injectable 
anesthesia (Marntell et al. 2005b).  
 
Rebound in health and disease 
Another important difference (and potential limitation) of our study, compared 
with other investigations, is the fact that we included only healthy horses, 
whereas the most of the clinical patients and many of the research animals used 
in other studies were unhealthy. A rebound effect appears to be more likely in 
humans with pulmonary hypertension, acute respiratory distress syndrome, 
hypoxemic respiratory failure, pulmonary hypertension or during or following 
cardiothoracic surgery or lung transplantation. Among other animals with 
disease, pigs with endotoxemia (Chen et al. 2001) and neonatal sheep with 
pulmonary hypertension (Ross et al. 2005) can also develop the rebound effect. 
Because ET synthesis is increased in disease states (Sanai et al. 1996),(48) an 
ET-induced rebound effect may be more likely to develop in diseased patients 
than in healthy patients. Also, the etiology of the rebound effect was different 
following iNO withdrawal in lambs with normal pulmonary circulation and 
those with PAH (Ross et al. 2005). The type of disease may also affect the 
rebound response as rebound has not been reported in patients with chronic 
PAH or COPD (Vonbank et al. 2003, Barst et al. 2012). iNO does not cause a 
rebound effect in healthy humans breathing iNO for a short duration (Sanchez 
Crespo et al. 2010) or our healthy horses. Thus, PiNO delivery to horses with 
disease that might cause the rebound effect needs to be studied. 
4.2.2  Accumulation of NO in the circuit 
With the delivery of PiNO rather than CiNO, the total dose and dose length of 
iNO is decreased and delivered during the first part of the breath, which 
decreases the chance of NO accumulation in the rebreathing system. The 71 
 
delivery unit was placed at the close to the patient, at the junction of the 
endotracheal tube and the circle breathing system, thus minimizing the chance 
that inhaled NO will react with oxygen to form NO2 since the likelihood of the 
reaction increases as the time NO and oxygen are in contact increase. In 
Studies I and II (MIGET), there were no detectable levels of NO in the circuit 
within 5 minutes after discontinuing administration, which virtually eliminates 
the chance that exhaled NO will be available to react with oxygen to create 
NO2. NO2 was not detected in the circuit at any time in Study III. Gradual 
weaning from iNO alleviates the chance of a rebound effect (Bloch et al. 2007) 
and residual NO in the circuit could have produced an inadvertent ‘weaning.’ 
However, since no NO was detected in the circuit, the lack of a rebound effect 
was not the result of a weaning effect from retained NO. 
In humans, dosages of 5-80 ppm of continuously delivered iNO are most 
commonly reported (Ichinose et al., 2004, Griffiths and Evans, 2005, Bloch et 
al., 2007, Creagh-Brown et al., 2009). With PiNO in humans, dosages of are 
reported as mls/breath (Barst et al. 2012). In our horses, the dose was based on 
delivery of PiNO for a certain percentage of the time of inhalation and this is 
the most practical way to deliver PiNO in the clinical setting with the current 
delivery method. In reality, the dose was administered ‘to effect’ since we 
based our therapeutic pulse length on the lowest duration pulse that would 
provide the greatest change in PaO2 and Qs/Qt. The dose delivered to effect as 
a pulse rather than continuously results in a decreased amount of NO in the 
system and, thus, less accumulation. 
Inhaled NO can cause adverse effects other than just the rebound effect and 
production of nitrous dioxide. Methemoglobinemia, pulmonary cellular 
proliferation (due to increased cGMP), DNA strand breaks, production of a 
cytotoxic oxidant (peroxynitrite), and blockade of platelet aggregation are all 
related to iNO (Weinberger et al. 2001). However, these adverse effects are 
uncommon and primarily caused by excessively high dosages. Even at the high 
end of clinically used dosages, side effects are uncommon. For instance, iNO 
of anything less than 100 ppm iNO is unlikely to cause clinically significant 
methemoglobin in children or adults with normal hemoglobin function (Barst 
et al. 2012). 
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4.3  Mechanism of action of PiNO 
Because the classic mechanism for PiNO-induced improvement in PaO2 and 
Qs/Qt is relief of pulmonary hypertension and our horses were not 
hypertensive, the question of mechanism of action remains unanswered.  
4.3.1  Contribution from areas of low VA/Q and Qs/Qt 
Using MIGET in Study II, we suggested that improvement of pulmonary 
function is due to redistribution of the blood flow with subsequent 
improvement in VA/Q matching and decreased Qs/Qt. However, the question 
of whether redistribution occurred at individual alveoli scattered throughout the 
entire lung or by mass movement of blood flow away from the dependent 
atelectatic Qs/Qt area was not answered. For redistribution to occur in 
individual alveoli throughout the entire lung, alveoli with low VA/Q (low 
ventilation) and intermittent opening would have to be recruited to consistently 
participate in gas exchange. However, based on the fact that alveoli with low 
VA/Q are not likely the major cause of hypoxemia (Data from Study IIMIGET 
and (Nyman et al. 1990), it is unlikely that recruitment of these alveoli will 
make a major impact. Because the Qs/Qt was identified as a major contributor 
to hypoxemia in our studies (using Berggren shunt equation in Studies I-V and 
MIGET in Study II) and was defined as the primary cause of hypoxemia in a 
former study (Nyman et al. 1990), it may be more likely that blood perfusing 
the Qs/Qt is actually redistributed by a mass movement of blood from the 
atelectatic region to regions with ventilation. However, this would require 
blood to move against gravitational pull because the shunting occurs in the 
dependent lung regions (Nyman et al. 1990).  
4.3.2  Pulmonary blood flow distribution in the horse 
To redistribute away from the dependent lung regions in the dorsally 
recumbent horse blood would also have to move against its normal perfusion 
pattern. As with many other mammalian species (Mure et al. 2000) (Nyren et 
al. 1999, Walther, Domino and Hlastala 1998) (Walther et al. 1997), 
pulmonary blood flow distribution in the horse may be somewhat controlled by 
gravity but gravity is not the strongest factor. In fact, although markedly 
heterogenous, distribution appears to be ‘opposite to gravity’ in the standing 
conscious horse lung, with flow increasing as the vertical distance up the lung 
increases  (Hlastala et al. 1996). Blood flow appears to be preferentially 
directed to the caudo-dorsal regions of the lung as determined in anesthetized 
ponies maintained in the prone position (Jarvis et al. 1992), standing and 
exercising horses (Bernard et al. 1996, Erickson et al. 1999), and standing and 
exercising horses with or without respiratory disease (Harmegnies et al. 2002). 73 
 
Distribution that is not solely controlled by gravity is also present in the 
anesthetized recumbent horse (Staddon and Weaver 1981, Dobson et al. 1985), 
prompting Dobson & Gleed to state, ‘an unidentified factor overrides 
gravitational effects under our conditions of anaesthetization’ (1996). The lack 
of gravitational control over perfusion distribution is also evident in other 
species. In the prone position, perfusion is distributed selectively to the dorsal 
diaphragmatic region but perfusion loses its selectivity and becomes more 
uniform when the person (Mure et al. 2000) or pig (Nyren et al. 1999) or dog 
(Walther et al. 1998) or sheep (Walther et al. 1997) is in the supine position. 
The uniformity of perfusion decreases VA/Q matching and oxygenation in the 
supine position.  
This preferential distribution ‘against gravity’ is likely due to the 
vasodilatory effects of endogenous NO. In humans, nitric oxide synthase 
expression and nitric oxide production are significantly higher in dorsal 
compared to ventral lung regions (Rimeika et al. 2004). In isolated swine 
arterial rings from various lung regions, NOS activity and vasorelaxation in 
response to endothelium-dependent induction of endogenous NO production 
was greater in dorsal than in ventral pulmonary arterial rings (Rimeika et al. 
2006). Pelletier et al. (Pelletier et al. 1998) compared vasorelaxation of equine 
pulmonary arteries from the caudo-dorsal (non-dependent) and cranio-ventral 
(dependent) lung in response to endothelium-dependent induction of NO 
production. Profound relaxation occurred in caudo-dorsal vessels but only a 
slight relaxation, followed by a profound contraction, occurred in the cranio-
ventral vessels. The spatial location of the responses likely explains the spatial 
distribution of pulmonary blood flow. However, the reason for the differing 
spatial responses is unknown. The following explanations have been offered: 
difference in responsiveness of vascular smooth muscle to NO; differences in 
the magnitude of the endothelial production or release of NO; differences in 
inactivation of NO by oxygen radicals or by NO diffusion to the vascular 
smooth muscle (Pelletier et al. 1998).  
Regardless of the cause of the spatiality of the perfusion distribution, the 
preferential caudodorsal perfusion in the horse means that pulmonary perfusion 
in a horse in the dorsal or supine position will preferentially be distributed to 
the same area that has been made atelectatic by compression from the 
diaphragm and viscera. This again would necessitate a movement of blood up 
the vertical plane of the lung if our theory of mass movement is correct. 
4.3.3  Pulmonary blood flow redistribution: scintigraphy 
The actual spatial distribution (or redistribution) of blood flow in the lungs can 
be visualized in two dimensions by perfusion scintigraphy. The small particles 74 
 
of radioactive albumin injected during each examination are completely lodged 
in the pulmonary vascular bed in the first pass of the injected volume and the 
distribution and intensity of the radioactivity in the lung is proportional to the 
distribution and rate of the pulmonary blood flow. Scintigraphy has been used 
to study distribution or redistribution of blood flow in standing horses, 
exercising horses and horses with pulmonary disease (Harmegnies et al. 2002, 
Votion et al. 1999a, Votion et al. 1997, Votion et al. 1999b, Votion and 
LeKeux 2003, O'Callaghan et al. 1987, Bernard et al. 1996, Erickson et al. 
1999, Hlastala et al. 1996).  
In Study V, scintigraphic images indicated that, during PiNO delivery, the 
pulmonary blood flow was redistributed en masse from dependent, presumably 
non-ventilated, regions of the lung to non-dependent, presumably better 
ventilated, regions of the lung (Figure 21, 22, 23). The blood flow returned to 
the baseline regions 30 minutes following cessation of PiNO.  This is a major 
finding in our study since a mass movement of blood flow away from gravity, 
although hypothesized to be the mechanism of action, is still somewhat 
surprising because of the large vertical gradient that the blood must move in 
the horse thorax and because of the fact that blood must move from the 
preferential area of distribution. We did not pursue the mechanism of the mass 
redistribution but it is likely two-fold, with PiNO-mediated vasodilatory effects 
in the non-dependent lung and PiNO-mediated vasoconstriction in the 
dependent lung. The latter mechanism is postulated on the fact that, in healthy 
pig lungs, iNO downregulates endogenous NO production and causes 
vasoconstriction in hypoxic lung regions distal to the lung regions receiving 
iNO (Hambraeus-Jonzon et al. 1998, Hambraeus-Jonzon et al. 2001). 
Conversely, in endotoxemic pigs, iNO causes an increase in endogenous NO 
production in lung regions distal to the lung regions receiving iNO. This may 
cause vasodilation in the distal segments, counteracting the iNO-induced 
increase in blood flow to the ventilated lung regions and potentially 
contributing to hypoxemia (Nilsson et al. 2010). This underscores the need to 
investigate PiNO in compromised horses. 
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Figure 21. Images of relative blood flow before (control), at end of treatment with PiNO 
delivered for 30 minutes (treatment) and 30 minutes after cessation of inhalation of PiNO 
(recovery). The left upper border is defined by the diaphragm, the lower border by the spine, and 
the right border by the edge of the field of view of the gamma camera. The yellow lines define the 
non-dependent ventral (with increased flow) and the white lines the dependent (dorsal) (with 
decreased flow) ROIs. They were copied from the functional images in Figure 6.The images were 
made by subtracting the NO treatment image from the baseline image.  After inhalation of PiNO, 
the flow in the non-dependent ventral regions increases (colors more towards the red) and in the 
dependent dorsal regions decreases (colors more towards the blue). At 30 minutes after cessation 
of NO inhalation, flows have reverted to approximately the baseline. The field of view is 
indicated in yellow in the horse sketch to the right of the images. To facilitate drawing the ROIs, 
especially the isocount line between them, the color scales were adjusted to enhance the contrast 
between the two ROIs. The color scales have been adjusted in each image to maximize contrast 
between ROIs so the images are not directly comparable. 
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Figure 22. Relative flow in the  dependent (dorsal) and nondependent (ventral) regions of interest 
(ROIs) as percentage of total flow in both ROIs. The percentage of blood flow to the 
nondependent lung regions increased while the percentage of blood flow to the dependent lung 
regions proportionately decreased during PiNO, and returned to baseline levels 30 minutes after 
cessation of PiNO.   
 
A limitation of scintigraphy is that it is a two-dimensional process and the lung 
is a three-dimensional organ. Thus, we could determine the vertical movement 
of the blood but could not discern the magnitude of the redistribution 
horizontally across the lung. However, using CT and necropsy results, the 
horizontal distribution (not redistribution) was shown to be equally distributed 
across both lung fields in anesthetized horses (Nyman et al. 1990).  For future 
studies it might be possible to use single photon emission computed 
tomography (SPECT), which provides a more complete 3-D picture of the 
redistribution of the blood flow in the lungs. Using SPECT in anesthetized 
pigs, the atelectatic dependent zone was shown to be uniformly distributed 
across the lung fields (Strang et al. 2010). The injection of fluorescent 
microspheres into the circulation can also be used to determine 3-D blood flow 
and this has been extensively used in horses (Dobson et al. 1985, Sinclair et al. 
2000, Lerche 2006). However, limitations of this technique include the fact 
that final data collection requires sacrifice of the horse, microsphere size can 
skew data, tissue sampling size and location can skew data and drying of the 
lung can change the size and configuration, which can also skew the data. 
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4.3.4  Pulmonary ventilation and blood flow redistribution: MIGET 
Data were collected using MIGET at the same time as the scintigraphic scans 
and RSS was low in all studies, indicating a good fit of our model to the data. 
With MIGET we demonstrated that Qs/Qt decreased significantly during PiNO 
compared to PrePiNO which resulted in a prompt increase in PaO2 and SaO2 
(Figure 23 and Table 2). VA/Q matching (as determined by logSDQ) improved 
in all horses at PiNO but the improvement was not significant (Figure 24). 
Indices trended toward PrePiNO baseline at PostPiNO and were not different 
from PrePiNO. 
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Figure 23.  Oxygenation and shunt data 
from horses anesthetized with isoflurane 
and oxygen before (PrePiNO), during 
(PiNO) and after (PostPiNO) delivery of 
PiNO (Study V). 78 
 
 
 
 
Figure 24. MIGET data from one horse anesthetized with isoflurane and oxygen before 
(PrePiNO; upper left graph), during (PiNO; upper right graph) and after (PostPiNO; lower graph) 
delivery of PiNO (Study V). 
 
Changes in oxygenation, Qs/Qt and VA/Q were minimal in horse 3 
compared to horses 1 and 2, as can be seen by the individual data (Figure 25). 
This was due to the respiratory pattern of Horse 3, which unveiled a limitation 
of the PiNO delivery unit. The unit can deliver a pulse in a maximum of 8 
breaths/min and Horse 3 was breathing 12 breaths/min, resulting in a delivery 
of PiNO in every other breath rather than every breath. The limitation is 
described in the operation manual of the unit: ‘The breath cycle shall be at least 
7 seconds long and RR less than or equal to 8. With shorter breath time, false 
triggering may occur’. False triggering is activation of the unit without delivery 
of PiNO. This horse also had a very low tidal volume (as can be seen by 
minimal changes in lung volume detected by scintigraphy in Figure 26) so the 
low tidal volume combined with the rapid respiratory rate meant that Horse 3 
received a very low dose of PiNO and had a low, yet still measurable, 
response. The RR and TV were different from the other horses but were not 
outside the normal limits of anesthetized horses. However, because the RR and 
TV were outside the limits of the delivery unit, the pulsed dose was too small 
to achieve maximum effect. As with the delivery of PiNO20% (Study I), the 
small volume of PiNO probably reached the conducting airways but the 
delivery to the gas exchange regions of the lung was minimal.  79 
 
 
 
 
Figure 25 Response of individual isoflurane anesthetized horses to PiNO (Study V). The scale on 
the left is mmHg (for the PaO2) and percent (for the Qs/Qt). Note that PaO2 goes up and Qs/Qt 
goes down during PiNO administration and then values return to or trend to baseline (PrePiNO) 
30 minutes after PiNO cessation (PostPiNO). Horse 2, which had the largest Qs/Qt and was one 
of the most hypoxemic, had the most significant response to PiNO. 
 
 
 
 
Figure 26. Change in area of the lungs between end expiration (solid lines) and peak inspiration 
(dotted lines). Horse 3 has minimal change in area, indicating a much lower tidal volume than the 
other two horses. 
 
 
The major limitation of this portion of the project is that only 3 horses were 
studied. However, MIGET and scintigraphy were measured simultaneously, 
allowing us to determine that the distribution of the blood flow visualized with 
scintigraphy changed at the precise time that the Qs/Qt was decreased and the 
VA/Q more evenly matched during PiNO. The use of the MIGET to determine 
VA/Q matching has been validated as the gold standard technique in conscious 
(Hedenstierna et al. 1987) and anesthetized (Nyman and Hedenstierna 1989) 
horses and has been used to demonstrate changes in matching during PiNO 
(Heinonen et al. 2001). Scintigraphy has previously been shown to detect 80 
 
changes in regions of blood flow in exercising horses and horses with lung 
pathology (Hlastala et al. 1996, Bernard et al. 1996, Erickson et al. 1999). 
Furthermore, all major parameters of interest (PaO2, SaO2, Qs/Qt, and 
pulmonary blood flow) trended significantly in the same direction in all three 
horses, even in the horse receiving a very low dose of PiNO. Because of the 
consistent changes in all 3 horses, the simultaneous measurement of MIGET 
and scintigraphy and the fact that both techniques are sensitive and specific for 
the indices we were measuring, we contend that our results are robust in spite 
of the low number of animals used.  
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Conclusions 
 
With our data, a major question – ‘can perfusion, rather than ventilation, be 
changed to improve oxygenation in the anesthetized horse?’ – was answered in 
the affirmative. Blood flow, as evidenced by scintigraphy, was redistributed to 
the ventilated regions against gravity and preferential perfusion distribution in 
response to PiNO. This redistribution decreased Qs/Qt and improved both 
VA/Q matching and oxygenation in the anesthetized horse. This redistribution 
is an important concept for use of PiNO in anesthetized horses since it is this 
mechanism that provides the improvement in oxygenation. 
With the goal of introducing PiNO for clinical use in anesthetized horses, 
we have extended previous work which indicated that PiNO should be 
delivered in the early portion of inhalation. The most effective pulse-length of 
PiNO was 30-45% beginning with inspiration and we have proven that the 
response to uninterrupted delivery of the pulse is sustained over at least 2.5 
hours in both the dorsally and laterally recumbent horse. This duration is an 
important difference from previous studies where PiNO was delivered for only 
5 minutes. In our studies, the PiNO-mediated increase in oxygenation (PaO2, 
SaO2, Pv ̄ O2, Sv ̄ O2) and decrease in Qs/Qt was sustained and stable throughout 
the entire anesthetic period. Perhaps most importantly, we have shown that 
there is no deleterious or dangerous rebound response in healthy horses 
following withdrawal of PiNO and, in fact, PiNO has a prolonged effect that 
lasts throughout the 30 minute recovery time. The improved oxygenation and 
pulmonary function (as evidenced by decreased Qs/Qt) during recovery are 
major reasons to use PiNO in equine anesthesia since improved oxygenation 
during the recovery period could potentially improve recovery from anesthesia 
and decrease the incidence of ischemia-related conditions which are so 
prevalent in the horse. 
We are confident that PiNO is ready for clinical use. 
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5  Future Research and Limitations  
 
We have shown that redistribution of perfusion, rather than ventilation is the 
answer to improving oxygenation in the anesthetized horse and that 
redistribution of perfusion can best be produced by utilizing PiNO.  However, 
the mechanism that initiates the redistribution is unknown and perhaps could 
be elucidated in future studies.   
The major limitation of our study ‘preparing PiNO for clinical use’ is that 
we have used PiNO only in healthy horses. Thus, exploring the effects of PiNO 
in patients with abdominal compromise and endotoxemia is critical. Currently, 
PiNO is being used in compromised horses in the equine clinic at SLU 
(Nyman, personal communication, October 2012) and the results are positive. 
Perhaps the most interesting, and beneficial, research yet to be done would 
answer the question, ‘what is the real impact of anesthesia-induced hypoxemia 
in the horse? There is an argument that horses recover from anesthesia even if 
they are hypoxemic so why do we need to improve oxygenation? The 
argument continues that horses are incredible athletes and at maximum 
exercise are profoundly hypoxemic yet they recover rapidly and without 
adverse impact. But does the brief exercise-induced hypoxemia of the 
conscious exercising horse relate to the prolonged drug-induced hypoxemia of 
the anesthetized horse? Do horses really recover from hypoxemia during 
anesthesia ‘without incident’ or do we not know what ‘incidents’ to look for? 
Are we too focused on the early recovery in the recovery room without 
measuring the long term outcome? We have the power to decrease morbidity 
during and after anesthesia, especially in those horses that are compromised 
when they arrive in the induction stall.  To improve the outcome of equine 
anesthesia, we need: 
  a validated scoring system to assess the duration and quality of 
recovery and we need to use it in the clinics;  84 
 
  outcomes measurements that assess long term effect of anesthesia 
and surgery, i.e. postoperative wound infections, myopathies, 
neuropathies, inflammation, etc…   
  pre-, intra- and postoperative prognostic markers for tissue 
hypoxemia are (eg lactate and venous oxygen saturation) that are 
correlated to outcome. 
Finally, we need to refine the equipment for clinical use (ie, mechanical 
ventilation, different breathing rates, etc…). 
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